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ABSTRACT 
 
Introduction 
A protocol has been devised in which a 20ml mixture of hyperbaric bupivacaine and 
fentanyl is prepared in a multi-dose syringe, from which aliquots are withdrawn into 
individual sterile syringes for use in spinal anaesthesia.  The risk of microbial 
contamination of these multi-dose syringes is unknown and this study was designed 
to assess such risk.  
 
Methodology 
In this pilot study, each syringe was prepared using non-aseptic technique to contain 
a mixture comprising Fentanyl 10 μg.ml-1, Bupivacaine 4mg.ml-1and Dextrose 
64mg.ml-1, with a total volume of 20ml.  Syringes were then allocated to pairs.  
Aliquots were withdrawn hourly from one syringe of each pair for a twelve-hour 
study period, whilst the other syringe was sampled only at the beginning and end of 
the same period.  All aliquots were withdrawn using standard aseptic technique in an 
operating theatre environment.  For each syringe pair, both samples from the control 
syringe and four of the samples from the multi-dose syringe were submitted for 
microbiological culture.  
 
Results 
Of the 120 samples taken, one sample was excluded.  Of the remaining 119 samples 
submitted for microbiological investigation, only one yielded growth.  This sample 
had been taken from a multi-dose syringe at the beginning of the study period.  
Subsequent samples withdrawn from the same syringe were found to be sterile.  The 
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organism which had been cultured from this sample was Staphylococcus aureus (S. 
aureus). 
 
Conclusion 
It is possible that the culture medium which yielded the microbial growth was 
contaminated, which would explain why subsequent samples from the same syringe 
were sterile.  Alternatively, bupivacaine is known to be strongly antimicrobial against 
some pathogens and it is conceivable that there may have been initial contamination 
of the syringe by S. aureus, which was inhibited by the bupivacaine to produce 
subsequent sterile samples.  Whilst this may suggest that the use of multi-dose 
syringes for spinal anaesthesia could be safe, in light of the inconclusive result, 
further investigation is warranted. 
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NOMENCLATURE 
 
Aerobic organisms: organisms which require oxygen in order to survive 
Anaerobic organisms: organisms which require a lack of oxygen in order to survive 
Arachnoiditis: inflammation of one of the meninges called the arachnoid mata 
Cephalad: towards the head 
Dermatome: an area of the body which is supplied by a single spinal nerve root 
Dura (also dura mata): outermost covering of the brain and spinal cord 
Epidural abscess: collection of pus in the space outside of the meninges caused by 
infection 
Hypotension: low blood pressure 
Lumbar lordosis: the curvature of the spinal column convex anterior (forwards) at 
the level of the lower back 
Meningitis: inflammation of the meninges, which are the layers of tissue covering the 
brain and spinal cord 
Minimum bactericidal concentration (MBC): minimum concentration of a drug or 
substance which will kill a specific type of bacterium 
Minimum inhibitory concentration (MIC): minimum concentration of a drug or 
substance which will prevent growth of a specific type of bacterium 
Opioids: group of synthetic drugs related to morphine 
Pathogen: microorganism which causes disease 
Supine: the position of lying on the back facing upwards 
Thoracic kyphosis: the curvature of the spinal column convex posterior (backwards) 
at the level of the chest
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CHAPTER 1: INTRODUCTION 
 
This Introduction will first present the background to the research question at hand 
and then will give an overview of the subsequent research report. 
 
1.1 Background 
 
1.1.1 Neuraxial blockade and obstetric anaesthesia 
 
The term “neuraxial drug administration” describes techniques that deliver drugs 
into the vicinity of the spinal cord (1) with “neuraxial blockade” referring to the 
introduction of local anaesthetics and adjuvant drugs in order to create blockade of 
transmission through motor and sensory nerves.  
 
In the 1960s, maternal mortality in association with anaesthesia was estimated to be 
around 36 per 100 000 caesarean sections.  The majority of these deaths resulted 
from difficulty in airway management.  In more recent years, the maternal death rate 
has decreased substantially to 1 death per 100 000 caesarean sections, correlating 
with the increasing use of neuraxial blockade for caesarean section.  The use of 
neuraxial blockade allows the patient to maintain control of her own airway, 
decreases the risk of loss of airway control and thus decreases the maternal mortality 
associated with anaesthesia (2).  For this reason, evidence increasingly suggests that 
neuraxial blockade is safer than general anaesthesia for pregnant women. The most 
recent recommendations by the American Society of Anesthesiologists state that 
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“neuraxial techniques are preferred to general anesthesia for most caesarean 
deliveries”(1).  It is the author’s experience that the commonest type of neuraxial 
blockade used for caesarean section in South African hospitals is spinal anaesthesia, 
where local anaesthetics and adjuvant drugs are introduced into the intrathecal 
space.  Here, they act by blocking sodium channels and preventing electrical 
conduction through the spinal nerve roots and spinal cord (3). 
 
1.1.2 Agents used to produce spinal anaesthesia 
 
Various combinations of medications have been used to achieve spinal anaesthesia.  
The most widely used combination at Chris Hani Baragwanath Hospital (CHBH) is 
hyperbaric bupivacaine and an opioid, fentanyl.  Bupivacaine is an amino-amide local 
anaesthetic with relatively slow onset and prolonged duration of action (4).  When 
bupivacaine is mixed with dextrose, the resulting combination is denser than the 
cerebral-spinal fluid into which is it injected, hence making it settle according to 
gravity.  The use of this “hyperbaric” bupivacaine allows for the local anaesthetic to 
sink to the most dependent part of the thoracic kyphosis in the supine patient, which 
provides a T6 dermatomal level of anaesthesia (Figure 1.1).  This level is sufficiently 
high to allow for some abdominal surgery, such as caesarean section.  Fentanyl is a 
potent, lipophilic opioid (1).  When added to the mixture for spinal anaesthesia, 
fentanyl decreases dose requirement of bupivacaine, decreases the incidence of 
hypotension associated with spinal anaesthesia, and prolongs the duration of 
postoperative analgesia, as compared with bupivacaine alone (5). 
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Figure 1.1: Schematic diagram indicating cephallad spread of hyperbaric bupivacaine 
in the supine patient 
 
1.1.3 Protocol for preparing drug mixture in a multi-dose syringe 
 
There are various methods of preparing this mixture of local anaesthetic, dextrose 
and opioid in the proportions required for spinal anaesthesia.  A protocol has been 
devised at CHBH in which a 20ml syringe is used to prepare an appropriate mixture 
of proprietary hyperbaric bupivacaine and fentanyl (Appendix A).  Small aliquots of 
this mixture are then drawn out of this 20ml syringe into smaller, sterile syringes, 
each of which is used to produce spinal anaesthesia in a different patient.   
 
1.1.4 Current opinion on the use of multi-dose syringes 
 
Guidelines published by the American Society of Anaesthesiologists (ASA) regarding 
preparation of medications for parenteral administration recommend that single 
dose items be used for one patient only and that medications be drawn up into a 
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syringe immediately before administration (6).  The position of the South African 
Society of Anaesthesiologists (SASA) is to discourage ampoule-sharing between 
patients as a method to limit costs (7).  However, these and other similar guidelines 
have largely been established based upon assumption of good practice, rather than 
broad-based evidence.  Further, the practice of using multi-dose vials of local 
anaesthetic for neuraxial blockade has been noted in several developing countries 
owing to limited resource availability (8), despite international recommendations to 
the contrary. 
 
1.1.5 Concern over microbial contamination of multi-dose syringes 
 
Whilst it appears that the use of such multi-dose syringes is common, there are 
concerns over the possibility of microbial contamination of the drug mixture during 
the period between preparation and administration.  This is especially relevant if this 
period is prolonged.  Of particular concern are several points: 
1. Pathogens which are inoculated directly into the intrathecal space bypass 
various immune barriers which would otherwise need to be evaded before the 
pathogen could cause meningitis.  These barriers are the mucosal epithelium, 
intravascular cellular and humoral immunity and the blood-brain barrier (9).  
Since the cerebrospinal fluid (CSF) provides an excellent culture medium for 
certain pathogens and with a paucity of immune-mediating cells in the 
intrathecal space, organisms deposited directly into the CSF multiply rapidly 
and produce a fulminant meningitis within hours of inoculation (9).  
Therefore, any microbial contamination of a drug intended for intrathecal 
administration is potentially clinically significant. 
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2. The drug mixture described above necessarily contains dextrose in order to 
make it hyperbaric.  There have been contradictory findings as to whether 
dextrose-containing solutions of varying concentrations support or inhibit 
bacterial growth (10).  It has been known since as early as 1909, and more 
recently re-examined, that many local anaesthetics, in fact, exert an 
antimicrobial effect (11).  This knowledge has been used by some clinicians to 
justify the safety of using a multi-dose syringe technique. 
3. Drug preparations used for intrathecal injection must be preservative-free in 
order to avoid the chemical arachnoiditis which many preservatives have been 
shown to cause (12).  This raises further concern for the possibility of 
microbial contamination of these drugs if left drawn up in syringes in the 
operating theatre environment. 
4. By necessity, the use of a multi-dose syringe demands that needles, albeit 
sterile ones, make multiple entrances into the multi-dose syringe in order to 
withdraw aliquots for clinical use.  It is the author’s concern that these 
multiple entries and the turbulence which they cause in the drug mixture in 
the multi-dose syringe may exacerbate the risk of microbial contamination of 
the contents of the syringe. 
 
1.1.6 Implications of potential microbial contamination 
 
The injection of anaesthetic agent which has been contaminated by pathogens can 
lead to meningitis or abscess formation.  Whilst the incidence of these appears to be 
low (9,13),  long term neurological sequelae are potentially catastrophic.  Therefore, 
every reasonable precaution should be taken to prevent these complications.  Studies 
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which have been conducted on drugs intended for epidural administration have 
suggested that microbial growth is inhibited by local anaesthetics.  However, only one 
of these studies examined mixtures containing dextrose (14), and none were 
conducted in the clinically-applicable context of the operating theatre environment. 
 
1.2 Definition of research question 
 
1.2.1 Problem Statement 
 
Multi-dose syringes containing drugs intended for intrathecal injection may be 
subject to microbial contamination, which may be exacerbated by frequent sampling 
from the syringe over the course of time.  The consequences of microbial 
contamination may be considerable, and therefore there is a need to determine the 
risk of this contamination.  
 
1.2.2 Aim 
 
A pilot study was designed to explore the risk of microbial contamination of syringes 
containing a mixture of hyperbaric bupivacaine and fentanyl in the operating theatre 
environment.  The aim of this study was to establish whether microbial 
contamination of drugs prepared in a 20ml syringe according to the protocol occurs.  
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1.2.3 Objectives 
 
1.2.3.1  Primary objectives 
a) To determine whether there is microbiological growth in the drug mixture of 
hyperbaric bupivacaine and fentanyl prepared in multi-dose syringes from 
which aliquots are withdrawn hourly. 
b) To compare the microbiological growth in samples from the multi-dose 
syringes with any growth in the mixture prepared in a control syringe from 
which no aliquots are withdrawn during the same 12 hour period. 
 
1.2.3.2 Secondary objectives 
a) To determine whether microbial growth in the syringes is influenced by 
ambient theatre temperature. 
b) To determine whether number of cases done in the theatre during the study 
period influences microbial contamination of the syringes. 
 
1.2.4 Methodology 
 
A prospective longitudinal pilot study was designed to give an indication of whether 
the use of a multi-dose syringe poses a clear risk to the patient.  The methodology of 
this initial study was kept as simple as possible so as to avoid confounding factors.  
The intention was to use the data collected during the pilot study to inform a future 
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definitive study if the pilot did not indicate that the use of the multi-dose syringe 
protocol was clearly hazardous. 
 
1.3 Summary of introduction 
 
A protocol has been devised in which a 20ml mixture of hyperbaric bupivacaine and 
fentanyl is prepared in a multi-dose syringe, from which aliquots are withdrawn into 
individual sterile syringes for use in spinal anaesthesia.  The risk of microbial 
contamination of these multi-dose syringes is unknown and this study was designed 
to assess such risk.  
 
First, a systematic literature review was performed in order to gain an understanding 
of current knowledge (Chapter 2).  Then a pilot study was designed in order to 
establish whether contamination occurs as a rule (Chapter 3).  Results are presented 
(Chapter 4) and discussed (Chapter 5) in the latter part of the report.  Conclusions 
and insights for future studies are presented in Chapter 6.
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CHAPTER 2: LITERATURE REVIEW 
 
The current study examines the risk of occurrence of microbial contamination of 
multi-dose syringes containing a mixture of hyperbaric bupivacaine and fentanyl in 
the operating theatre environment.  Thorough literature review revealed that this 
specific subject has never before been investigated.  However, valuable work has 
been done in related areas which may offer some insight into various contributory 
factors.  These various factors are to be discussed in the following Literature Review. 
 
2.1 Methodology for Literature Review 
 
2.1.1 Design of literature review 
 
This literature review was designed to examine various aspects of the topic. First, the 
literature was reviewed to establish whether microbial contamination of a solution 
intended for intrathecal use may be of clinical concern.  Then the literature was 
reviewed on the subjects of microbial contamination of: 
1) bupivacaine 
2) dextrose 
3) fentanyl 
4) multi-dose containers 
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2.1.2 Detailed methodology used for literature review 
 
The electronic database, Pubmed (http://www.ncbi.nlm.nih.gov/pmc), was employed 
for on-line literature searches.  Pubmed is a free digital archive of biomedical and life 
sciences journal literature administered by the United States’ National Institutes of 
Health.  The search parameters listed in Table 2.1 were used to conduct the searches 
on each subject.  English language journal articles from all dates were considered, and 
titles were scanned in order to compile a list of potential candidate studies.  Full text 
articles were then obtained for all of these candidate studies and assessed for 
applicability.  All references made in these candidate studies were also scanned for 
further potentially applicable studies.  
 
Table 2.1: Search parameters used for literature reviews 
Infectious Complications AND Spinal Anaesthesia 
[Bupivacaine OR Local Anaesthetic OR Local Anesthetic] AND [Microbial Contamination OR 
Antimicrobial] 
[Intravenous OR Dextrose]  AND Microbial Contamination 
Opioids AND Microbial Contamination 
Multi-dose AND Microbial Contamination 
 
 
2.2 Implications of microbiological contamination of agents 
intended for intrathecal administration 
 
2.2.1 Definition of the problem 
 
Introduction of microbes into the intrathecal space, as would occur if a contaminated 
agent was used for spinal anaesthesia, could potentially result in post dural puncture 
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infections, which usually take the form of either meningitis (PDPM) or epidural 
abscess (15).  It appears, however, that iatrogenic meningitis associated with 
neuraxial blockade occurs almost exclusively after spinal anaesthesia.  Epidural 
abscesses are more common following epidural catheter insertion, although do very 
rarely occur after spinal anaesthetic (16). 
  
2.2.2 Incidence 
 
Whilst most authors agree that the occurrence of infective complications following 
dural puncture is very rare (13,15,17), the actual incidence remains unknown (9,18).  
Previous work has estimated the incidence of post dural puncture meningitis at 
between 0 – 7.2/1 000 000 (15-17,19-22), whilst the incidence of epidural abscess 
following spinal anaesthesia is probably far lower (16).  The range of incidences 
estimated almost certainly reflects different patient populations, surveillance 
methods and sample sizes.  Under-reporting is probably also a major factor 
contributing to the difficulty in establishing the true incidence of these complications 
(15).  A large retrospective study carried out in Sweden noted that most 
complications of neuraxial blockade occurred in the orthopaedic population, with 
very few complications occurring in the obstetric population (16).  Presumably this 
population is generally young and healthy with intact immunity and are more 
resistant to infections in general.   
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2.2.3 The pathogens involved 
 
A review of 179 cases of PDPM revealed that 49% of these to have been caused by 
bacteria from the Viridans group of Streptococci (9).  This group of Gram-positive 
bacteria generally have a low virulence and are normal commensals of the upper 
respiratory tract, the female genital tract, the gastrointestinal tract and are most 
abundant in the oral cavity (17).  Meningitis caused by the Viridians group is unusual 
when not associated with dural puncture (17).  Other pathogens which have caused 
post dural puncture meningitis include Gram-negative bacteria and Staphylococci 
(20).  Epidural abscesses which are either sporadic or associated with neuraxial 
blockade are primarily associated with Staphylococcus aureus (13). 
 
2.2.4 Pathogenesis 
 
Ordinarily, for a pathogen to be able to cause meningitis, it needs to invade the host 
epithelium, gain access to the intravascular space, cross the blood-brain barrier and 
then survive in the cerebrospinal fluid (CSF) (9).  However, with dural puncture, 
pathogens may gain direct access to the CSF, thereby avoiding major host defences 
(23).  
 
During neuraxial blockade, microbes may be either intrinsic or extrinsic in origin (18) 
and may gain access to the cerebrospinal fluid in one of four ways:  
1. By haemotogenous spread from distant infectious foci 
2. By translocation of the patient’s skin flora along the puncture tract or catheter 
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3. By inoculation of pathogens spread by droplet infection from the respiratory 
tract of the person performing the procedure or 
4. By contamination of anaesthetic agents (21) or equipment (24) through failure 
of infection control methods (25).  
Whilst the first is exceedingly rare  (25), it would appear from the common pathogens 
involved that most cases of post-dural puncture meningitis result from droplet 
infection originating from the respiratory tract of the person performing the 
procedure (15,16,18,20) or from needle contamination following incomplete 
sterilisation of the skin (9,20).  
 
Cerebrospinal fluid provides an excellent culture medium for mouth and skin 
commensals.  Once these pathogens gain access to the CSF, they may multiply rapidly 
(9).  Because of this, the introduction of bacteria directly into the CSF probably causes 
meningitis in any patient, however healthy (19).  Within hours a fulminant meningitis 
may result (9), the complications of which may be severe and are discussed below.  
The literature reviewed made no estimate of bacterial load required to initiate an 
infection.  However, in light of the preceding points, it is expected that a very small 
inoculum may lead to clinical infection. 
 
In the case of epidural abscesses, it is assumed that direct trauma is cause by 
insertion of the spinal needle, particularly when technical difficulty is encountered in 
performing the dural puncture.  The resulting haematoma then provides an excellent 
nidus for growth of any organisms which may reach the haematoma by the same 
routes mentioned previously (13). 
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2.2.5 Risk factors 
 
2.2.5.1 Procedural risk factors 
The intrathecal space is breached during various diagnostic and therapeutic 
procedures.  Of 179 cases of post-dural puncture meningitis reviewed by Baer, only 
17 of them were associated with diagnostic lumbar puncture, with the rest being 
associated with introduction of agents into the intrathecal space for various reasons 
(9).  In fact, most cases of dural puncture-associated infections have been reported in 
association with administration of spinal anaesthesia (18,26).  It would therefore 
appear that the introduction of foreign substance into the intrathecal space increases 
the risk of infection. However, it is yet to be established whether intrathecal injection 
of local anaesthetics, as opposed to injection of opioids or clonidine alone, may be 
protective owing to the antimicrobial properties of these agents (21).   
 
2.2.5.2 Breach in aseptic technique 
Although epidemiological studies are lacking, breach of strict aseptic technique 
during the procedure may play a role (17).  Currently, there is little consensus as to 
what constitutes strict aseptic technique for neuraxial blockade, however most 
authors conclude that the factors listed in Table 2.2 are important (27).  The use of 
opioids drawn up from ampoules which have been opened in a non-sterile fashion 
(22) and the potential contamination of multi-dose vials (9,21) have been raised as 
possible points of concern. 
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Table 2.2: Important components of aseptic technique (after Hebl) (27) 
Major components 
 Removing watches and jewellery 
 Pre-procedural hand washing with antiseptic solution 
 Protective barriers 
  Surgical mask 
  Surgical hat 
  Sterile gloves 
 Appropriate selection and application of skin disinfectant 
 Proper sterile draping techniques 
 Maintenance of a sterile field 
 Appropriate dressing techniques 
Minor components 
 Proper use of bacterial filters during long term catheterisation 
 Prevention of catheter, hub and site violations 
 
2.2.5.3 Patient risk factors 
Risk factors for epidural abscess have been listed as compromised immunity 
(including that caused by infection with the Human Immunodeficiency Virus), 
disruption of the spinal column (for example, by trauma) and distant sources of 
infection (13).  However, in the retrospective study done in Sweden, of the 29 
patients with PDPM, only two were found to have co-morbidity (one had diabetes 
mellitus and the other was on corticosteroid replacement therapy for Addison’s 
disease) (16). 
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2.2.6 Sequelae of post-dural puncture infections 
 
The potentially devastating sequelae of post-dural puncture infections include 
paralysis and even death (15,27).  The literature is not clear on the incidence of 
specific sequelae of post dural puncture infections.  However, the Swedish study 
found that 21% of patients presenting with meningitis and 57% of those presenting 
with epidural abscesses associated with neuraxial blockade had undefined 
“permanent neurological damage” (16).  Halaby notes that meningitis caused by low 
virulence organisms such as the Viridians group Streptococci usually has a good 
prognosis.  However, he and his colleagues present a case where a young patient with 
no known immune-compromise died as a result of iatrogenic meningitis caused by 
Streptococcus salivarius, which is one of the Viridans Group of Streptococci (17).  
 
Baer reports that survivors of community acquired meningitis suffer from cranial 
nerve palsies in 19%, hemiparesis in 4%, quadraparesis in 1% and aphasia in 2%, 
with other long term sequelae known to be seizures and impaired cognition (9).  
Whilst the pathogenesis and pathogens involved in community acquired meningitis 
are different from PDPM, a warning is still clear that the long term sequelae from 
PDPM may be catastrophic. 
 
Grewal et al report that epidural abscesses of all causes carry a mortality of up to 
16%, with death being due to systemic sepsis or prolonged immobility.  They caution 
that there are many other neurological sequelae which depend upon site and severity 
of the abscess (13). 
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2.2.7 Minimizing the risk 
 
In view of the potentially devastating discussed above, it is essential that all possible 
precautions be taken to prevent the initial infection.  Most authors advocate the use of 
strict aseptic technique when performing dural puncture, including the use of face 
masks (9,13,15-24,26,27).  Of particular interest to the current study is that several 
authors have specifically cautioned against the use of multi-dose vials (9,21,28).  
Instead, they recommend the use of single-dose ampoules contained in individual 
sterile packs which avoid contamination upon opening (22).  The Deutshe Gesellshaft 
fur Anästhesiologie und Intensivmedizin (DGAI) recommends that single dose vials 
be used instead of multi-dose vials wherever possible, particularly when being used 
for multiple patients (29).  The America Society for Regional Anesthesia and Pain 
Medicine have published guidelines for hand washing, mask wearing and skin 
preparation (15).  The Centre for Disease Control (CDC) has published guidelines for 
infection control measures in central venous catheter placement, however there is no 
equivalent at this time for neuraxial blockade.  There is a need for various risk factors 
to be studied to allow for appropriate, evidence-based guidelines to be established 
(21).  It is hoped that the current study will contribute to this knowledge. 
 
2.3 Antimicrobial effects of bupivacaine 
 
2.3.1 Basic pharmacology 
 
As with other local anaesthetics, bupivacaine exerts its action by inhibiting the 
passage of sodium ions through ion-selective sodium channels in nerve membranes 
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(4).  This blockage of sodium ion channels slows the rate of depolarisation of the 
nerve membrane, which prevents an action potential from being propagated along it.  
Bupivacaine is an amide local anaesthetic with a slow onset (5 – 8 minutes) and long 
duration of action (1,5 – 2 hours) (5).  This long duration and a differential moto-
sensory blockade make bupivacaine a popular choice for use in obstetric anaesthesia 
(30). 
 
2.3.2 Past investigations into the antimicrobial activity of bupivacaine 
 
As early as 1909, Jonnesco suggested that “The substances [local anaesthetic agents] 
need not be sterilized since they are themselves antiseptic”(11).  Unfortunately, this 
statement was not further substantiated in the original publication.  From the 1950s, 
further research was prompted by a growing concern that, in some clinical situations, 
the antimicrobial properties of local anaesthetics may be disadvantageous (31,32).  
These situations would include those when local anaesthetics administered at the 
time of a procedure for collecting microbiological specimens may decrease microbial 
yield from specimens obtained, such as in diagnostic broncholavage.  Since then, 
interest in the antimicrobial activities of local anaesthetics have spread to clinical 
disciplines as diverse as dentistry (33), anaesthetics (34-42), otorhinolaryngology 
(43), pulmonology (44) and ophthalmology (45,46).  
 
2.3.3 Antibacterial actions of bupivacaine 
 
Mechanisms of bactericidal activity of local anaesthetics have been proposed to 
include changes to cell membrane fluidity and expansion caused by disturbance in 
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membrane molecular organisation.   This leads to fracturing and solubilisation of the 
bacterial cell membranes.  Changes also occur at the nuclear level, with alterations in 
the DNA and ribosomal configuration noted.  The nett result of local anaesthetics on 
bacteria include inhibition of growth, reduction in numbers of viable cells, lysis of 
protoplasts, permeability changes, ultra structural alterations and inhibition of the 
activity of membrane-bound enzymes (47). 
 
2.3.4 Findings of previous investigations into the antibacterial activity of 
bupivacaine 
 
Several studies have examined the antimicrobial properties of bupivacaine (Table 
2.3).  All have suggested that this activity is concentration-dependent 
(14,33,34,39,48-54), however there is conflicting evidence as to the specifics of 
bupivacaine’s antimicrobial activity.  Some suggest that bupivacaine has good action 
against a variety of pathogens at clinically significant concentrations (14,50,51,54).  
However, several studies indicated that, whilst bupivacaine inhibits some organisms 
at clinically-significant concentrations, others appear to be resistant to its 
antimicrobial effects.  Some authors suggest that bupivacaine 0.5% is ineffective 
against Pseudomonas aeruginosa (P. aeruginosa) (33,39,52,53), an observation which 
has been refuted by others (34,49,51,54).  Candida albicans (C. albicans) was also 
found to be largely resistant to bupivacaine in several studies (33,34,52) and one 
study noted Klebsiella species to be less susceptible to the antimicrobial effects of 
bupivacaine than other organisms (49).  Another study found bupivacaine to have no 
effect on the growth of Enterococcus faecalis (E. faecalis) (48), however the 
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Table 2.3: Summary of investigations into the antimicrobial properties of bupivacaine (continues over) 
  
AUTHOR CONCENTRATIONS 
OF BUPIVACAINE 
MICROBES 
STUDIES 
INCUBATION 
TEMP 
ADDITIVES TO 
BUPIVACAINE 
STUDY 
SETTING 
CONCLUSIONS 
Coghlan 
(2009)     
 
(39) 
0.06 – 1% E. coli, 
E. faecalis,  
P. aeruginosa, 
S. aureus 
35°C 
 
Not stated Laboratory Bupivacaine was active against S. aureus 
(MIC = 0.125 – 0.2%), E. faecalis (MIC = 
0.25%) and E. coli (MIC = 0/25%)but not 
against P. aeruginosa 
Pelz  
(2008)  
 
 
 
(33) 
0.0125 – 0.2% 311 bacterial 
strains & 14 
strains of  C. 
albicans  
35°C Preservative- 
free 
Laboratory 36 bacterial & 14 Candidal species were 
completely or partly resistant to bupivacaine.  
P. aeruginosa & E. faecalis were the most 
resistant strains.  MBC for bupivacaine was 
76 – 100%+ of that routinely used in clinical 
dental practice 
Tamanai-
Shacoori, 
(2004)     (48) 
0.08% E. coli,  
E. faecalis, 
S. aureus 
37°C Not stated Laboratory Bupivacaine had no effect on the growth of E. 
faecalis, but inhibited the growth of E. coli 
and S. aureus 
Goodman, 
(2002)     (14) 
0.008 – 0.38% S. aureus 37°C Dextrose (0.11 – 
4.15%) 
Laboratory MIC for bupivacaine at 48 hours was 0.25% 
Aydin  
(2001)  
 
 
(34) 
0.625 – 0.5% C. albicans,  
E. coli,  
P. aeruginosa, 
S. aureus 
Room 
temperature 
Not stated Laboratory Bupivacaine 0.25% & 0.5% reduced the 
viable cells of P. aeruginosa.  The results for 
the other microbes were not presented, but 
bupivacaine was noted to have poor 
antimicrobial effectiveness. 
Pere  
(1999)  
 
 
 
 
(49) 
0.0938%, 0.1875%, 
0.375% 
E. coli, 
K.pneumoniae 
P. aeruginosa,  
S. aureus,  
S. epidermidis 
S. pyogenes 
37°C Preservative-free Laboratory Bupivacaine 0.375% fully inhibited the 
growth of E. coli, P. aeruginosa & S. 
epidermidis.  Even the lowest concentration 
had a significant inhibitory effect on the 
growth of P. aeruginosa, S. epidermidis & S. 
pyogenes. K. pneumoniae was less well 
inhibited. 
Hodson (1999)  
 
(50) 
0.125%, 0.25%, 0.5% E. faecalis, 
S. aureus, 
S. epidermidis 
37°C Preservative-free Laboratory No growth of any species was noted in  
bupivacaine 0.5% or 0.25%.  All three species 
multiplied in bupivacaine 0.125%. 
21 
 
Table 2.3: Summary of investigations into the antimicrobial properties of bupivacaine (continued) 
AUTHOR CONCENTRATIONS 
OF BUPIVACAINE 
MICROBES 
STUDIES 
INCUBATION 
TEMP 
ADDITIVES TO 
BUPIVACAINE 
STUDY 
SETTING 
CONCLUSIONS 
Cook  
(1998) 
 
 (51) 
0.1%, 0.5% E. coli, 
E. faecalis, 
P. aeruginosa, 
CNS 
30°C Diamorphine Laboratory Viable counts for all organisms decreased over a 
7 day period for all formulations tested, but 
bupivacaine 0.5% had the greatest activity. 
Grimmond 
(1986)  
 
 
 
 
 
 
(52) 
0.05%, 0.125%, 
0.25%, 0.5% 
E. coli,  
C. albicans 
P. aeruginosa, 
 S. aureus, 
MRSA 
S. epidermidis 
 S. pyogenes.  
S. pneumoniae 
35°C Preservative-free Laboratory Bupivacaine was ineffective against C. albicans & 
P. aeruginosa.  MICs for the remaining species 
studied were 0.25 – 0.5%. 
Rosenberg 
(1985)  
 
 
 
 
 
 
(53) 
0.05%, 0.125%, 
0.25%, 0.5% 
B. cereus,  
E. coli, 
C. albicans, 
 P. aeruginosa,  
S. aureus,  
S. epidermidis, 
S. faecalis, 
S. pneumonia, 
 S. pyogenes,  
35°C Preservative-free Laboratory Bupivacaine 0.5% inhibited all organisms except 
P. aeruginosa.  Bupivacaine 0.25% inhibited S. 
epidermidis, S. pneumonia & S. pyogenes.  
Bupivacaine 0.125% had little effect. 
Zaidi 
(1977)  
 
(54) 
0.5% with serial 
dilutions 
E. coli, 
P.aeruginosa,  
S. aureus,  
S. pyogenes 
37°C Preservative-free Laboratory MBC for bupivacaine for all organisms tested was 
0.5% 
B. cereus = Bacillus cereus, C. albicans = Candida albicans, CNS = Coagulase Negative Staphylococcus, E.coli = Escherichia coli, E. faecalis = Enterococcus faecalis,   K. 
pneumoniae = Klebsiella pneumonia, MRSA = Methicillin-Resistant Staphylococcus Aureus, P. aeruginosa = Pseudomonas aeruginosa, S. aureus = Staphylococcus aureus, 
S. epidermidis = Staphylococcus epidermidis, S. pyogenes = Streptococcus pyogenes, S. pneumoniae = Streptococcus pneumonia,  
 
MIC = minimum inhibitory concentration, MBC = mean bactericidal concentration         
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concentration of bupivacaine used in their study (0.08%) was far below that which is 
used clinically in our setting. 
 
2.3.5 Effect of temperature on the antibacterial activity of bupivacaine 
 
It has been suggested that the temperature of local anaesthetics may also affect their 
antimicrobial activity.  The antimicrobial activity of lignocaine is considerably higher 
at 40 °C than at 37°C (55) and a clinical study has suggested that Staphylococcus 
aureus survives for a far longer time in lignocaine stored in a refrigerator than at 
room temperature (56).  This finding has been repeated in investigations of microbial 
survival in other types of medication (57).  Many of the candidate studies from our 
literature review examined the antimicrobial activity of bupivacaine at temperatures 
which were substantially higher than room temperature (14,33,39,48-54).  In the 
only study which did observe the antimicrobial activity of bupivacaine at room 
temperature, the local anaesthetic was found to have generally poor antimicrobial 
effectiveness (34).  Different ambient temperatures during the studies could, in part, 
explain the diverse results. 
 
2.3.6 Effect of preservatives 
 
Drug preparations used in intrathecal injections must be preservative-free to avoid 
causing a chemical arachnoiditis (12).  Whilst it seems unlikely that many 
preservatives commonly added to local anaesthetics exert an appreciable 
antimicrobial affect alone, there is some evidence that there may be a synergistic 
antimicrobial effect between preservatives and local anaesthetics (33).  Therefore, it 
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is important in examining previous studies to know whether drug preparations which 
were used contained preservative or not.  For some studies reviewed, this was 
information was not stated (34,39,48) and therefore extrapolation of their results to 
preservative-free drug mixtures should be approached with caution. 
 
2.3.7 The clinical environment vs. the laboratory environment 
 
 The clinical environment is very different from the laboratory environment, with far 
greater opportunity for bacterial contamination by direct hand contact with syringes 
and airborne contamination in the former (58).  All studies found in the literature 
examined the fate of microbes inoculated into a preparation of bupivacaine in the 
laboratory environment, and documented any decrease in microbial numbers in 
order to establish the antimicrobial effect of bupivacaine (14,33,34,39,48-54).  
 
2.4 Microbiological impact of the addition of dextrose 
 
2.4.1 Dextrose and bupivacaine 
 
Some authors of studies examining the antimicrobial effects of bupivacaine 
specifically excluded the use of nutritional substances to prevent confounding of their 
results (34).  However, dextrose is added to the bupivacaine used for spinal 
anaesthesia in caesarean sections.  The resultant mixture is denser than the CSF into 
which it is injected, allowing for the bupivacaine to gravitate to the thoracic kyphosis, 
and so achieve a dermatomal level sufficiently high for the surgery (Figure 1.1).  
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It has been noted that certain bacteria, especially Klebsiella, Enterobacter and 
Serratia species, possess the enzyme aldolase.  This enzyme splits dextrose into 
pyruvic acid and thus allows this organisms to metabolise dextrose (59).  Therefore, 
it is important to consider the implications of the additional of dextrose to the drug 
mixture under investigation.  One of the studies examining bupivacaine did use 
hyperbaric bupivacaine with dextrose concentrations of 0.11- 4.15% (14).  In this 
study, bupivacaine 0.25% with dextrose 4.15% was found to be inhibitory to S. 
aureus.  However, this study investigated the effects of hyperbaric bupivacaine on S. 
aureus only, and other studies have found bupivacaine to be particularly active 
against this species and less active against other species (33,39,48,49,52,53).  
Therefore, global conclusion on the antimicrobial properties of hyperbaric 
bupivacaine cannot be drawn from this one study. 
 
2.4.2 Studies of other dextrose-containing fluids 
 
Studies which have investigated microbial growth in dextrose containing solutions 
were also reviewed and summarised in Table 2.4.  There is an indication that higher 
concentrations (i.e. above 10%) of dextrose decrease the risk of microbial growth 
through an osmotic effect (60).  However, Crighton found both Dextrose 5% and 10% 
in water to sustain the growth of various organisms, noteably Klebsiella and Serratia 
(61). Mendie et al found that various microorganisms in fact metabolise dextrose, so 
making the environment more favourable for themselves (62).  The literature 
therefore suggests that certain pathogens are able to survive in concentrations of 
dextrose which are similar to those which will contribute to the drug mixture under 
investigation in our study. 
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Table 2.4: Summary of studies investigating microbial survival in dextrose 
Acineto. calcoaceticus = Acinetobacter calcoaceticus, Aerom. hydrophila = Aeromonas hydrophila , B. subtilis = Bacillus subtilis, C. albicans = Candida albicans, C. freundii = Citrobacter freundii ,  E. cloacae = 
Enterobacter cloacae,  E.coli = Escherichia coli, K. pneumonia = Klebsiella pneumoniae, P. aeruginosa = Pseudomonas aeruginosa, P. cepacia = Pseudomonas cepacia, S. albus = Staphylococcus albus, S. 
aureus = Staphylococcus aureus, S. epidermidis = Staphylococcus epidermidis,  Ser. marcescens = Serratia marcescens
AUTHOR CONCENTRATIONS 
OF DEXTROSE  
ORGANISMS STUDIED CONCLUSIONS 
Hugbo 
(1998)  
 
 
(10) 
2.5%, 5.0%, 10%, 
20% 
B.  subtilis,  
C. albicans 
E. coli, 
K. pneumoniae,  
P. aeruginosa,  
S. aureus,  
When starved organisms were added to dextrose, there was a decrease in generation rates 
with higher concentrations of dextrose.  Different organisms behaved differently and C. 
albicans showed neither increase nor decrease in viable number over the study period in any 
dextrose concentration.  P. aeruginosa and E. coli were unable to survive in >5% dextrose. 
Blech 
(1986)  
 
 
 
 
 
 
(59) 
10% 
 
Acineto. calcoaceticus,  
Aerom. hydrophila,  
C. freundii, 
E. coli,  
E. cloacae, 
Flavobacterium 
K. pneumoniae,  
P. aeruginosa,  
Ser. marcescens,  
S. aureus 
Dextrose 10% was found to be inhibitory for all species studies except for Klebsiella, 
Enterobacter and Serratia species. 
Gacia-
Caballero 
(1985)  
(60) 
5%, 10%, 20%, 30%, 
50%, 70% 
 
C  albicans, 
P  aeruginosa, 
S. epidermidis,  
Ser. marcescens 
Dextrose 10% allowed growth of C. albicans & Ser. marcescens.  
Dextrose 5% allowed growth of S. epidermidis, C. albicans, P. aeruginosa, and Ser. marcescens 
 
Crighton 
(1973)  
 
 
(61) 
3.3%, 5%, 10%, 20%, 
50% (in various 
media) 
 
Klebsiella species,  
P. aeruginosa, 
P. cepacia 
Serratia,  
S. aureus,  
S. albus,  
Serratia, Klebsiella and to a lesser extent Pseudomonas species grew in many fluids 
containing 5% and 10% dextrose 
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2.5 Implications of the addition of fentanyl 
 
2.5.1 Background to investigations into microbial contamination of opioids 
 
Several studies have examined the microbiological implication of the addition of 
opioids (of which fentanyl is an example) to local anaesthetics (40,48,50-53,63) or 
the risk of microbial contamination of opioids alone (64) (Table 2.5).  The reason for 
this area interest in existing literature is that epidural infusions often contain plain 
(non-dextrose containing) local anaesthetics and opioids, as well as other adjuvant 
drugs which are mixed in large-volumes with the view to infusion over a period of 
hours.  This has led to investigations into the risk of microbiological contamination of 
these particular drug mixtures. 
 
2.5.2 Microbial contamination of opioids in general 
 
Pethidine had some antimicrobial activity at clinically significant concentrations 
(52,63) which may be related to its local anaesthetic-like properties (52).  In contrast 
to this, however, an in-use clinical study found that morphine and pethidine prepared 
for titration for individual patients have a high rate of contamination during clinical 
use (64).  There is some evidence that sufentanil may have some synergistic 
antimicrobial activity when used in combination with bupivacaine (48), although 
another study found sufentanil to neither inhibit nor encourage microbial growth 
(40).  Tamanai-Shacoori suggests that this non-specific antimicrobial activity of  
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Table 2.5: Summary of studies of the microbial survival in opioids 
 
B. cereus = Bacillus cereus, C. albicans = Candida albicans, CNS = Coagulase-Negative Staphylococcus aureus, E. faecalis = 
Enterococcus faecalis, E. coli = Escherichia coli, K. enterobacter = Klebsiella enterobacter, MRSA = Methicillin-Resistant 
Staphylococcus sureus , P. aeruginosa = Pseudomonas aeruginosa, S. aureus = Staphylococcus aureus, S. epidermidis = 
Staphylococcus epidermidis ,S. faecalis = Streptococcus faecalis, S. pneumoniae = Streptococcus pneumoniae, S. pyogenes  = 
Streptococcus pyogenes, MIC = Minimum Inhibitory Concentration 
AUTHOR 
 
OPIOID STUDIED ORGANISMS 
STUDIED 
CONCLUSIONS 
 
Hodson 
(2009) 
(50) 
Fentanyl  2μg/ml & 4 
μg/ml 
 
E. faecalis 
 E. coli 
 P. aeruginosa 
S. aureus 
Fentanyl had no antibacterial effect in isolation 
or any synergistic effect when added to local 
anaesthetics. 
Guillier 
(2007) 
(40) 
Sufentanil 0.5 - 0.75 
μg/ml 
 
E. coli 
S. aureus 
S. epidermidis 
Sufentanil neither encouraged nor inhibited 
growth of thebacteria studied. 
Tamanai-
Shacoori 
(2004) 
 
(48) 
Sufentanil 0.38 µg/ml 
(with bupivacaine) & 
0.5µg/ml (with 
ropivacaine) 
E. faecalis 
E. coli 
S. aureus 
Sufentanil alone inhibited only the growth of S. 
aureus but increased the inhibitory effect of 
bupivacaine on the growth of all bacteria studied. 
Cook 
(1998) 
 
(51) 
Diamorphine 0.01% , 
0.1%, 1% (with 
bupivacaine) 
CNS 
E. faecalis 
E. coli, 
P. aeruginosa 
Formulations with 1% diamorphine had greater 
antimicrobial activity than those with lower 
concentrations of the opioid. 
Rota 
(1997) 
 
 
 
 
 
(63) 
Morphine: 2.5, 5, 10 & 
20 mg/ml                                     
Pethidine: 6.25, 12.5, 
25 & 50mg/ml                            
Fentanyl: 6, 12,5 & 50 
μg/ml 
CNS 
E. coli 
 K. enterobacter 
P. aeruginosa 
Proteus species 
MIC of Morphine was 10mg/ml for P. aeruginosa 
and 20mg/ml for others except for the Proteus 
species, which were not inhibited                                                                  
 Pethidine had the most antibacterial effect with 
an MIC starting at 6.25mg/ml (specifics not 
reported).                            
Fentanyl showed no antibacterial effect. 
Taylor 
(1997) 
(64) 
Morphine & pethidine 
 
Opioids in 
clinical use 
sampled & 
cultured 
12% yielded microbiological growth, but no 
distinction wasmade between morphine and 
pethidine. 
Grimmond 
(1986) 
 
 
 
 
(52) 
Pethidine 0.5 - 
50mg/ml 
 
C. albicans 
E. coli 
MRSA 
P. aeruginosa 
S. aureus 
S. epidermidis 
S. faecalis 
S. pneumonia 
S. pyogenes 
At concentrations of 5mg/ml, pethidine inhibited 
6 of 10 organisms.  Resistant organisms were P. 
aeruginosa, S. aureus and C. albicans (MIC for 
these was 12,5mg/ml) and S. faecalis (MIC was 
25mg/ml). 
 
Rosenberg 
(1985) 
 
 
 
 
(53) 
Morphine 0.2 & 
2mg/ml (with 
bupivacaine) 
 
B.cereus 
C.albicans 
E.coli 
P.aeruginosa 
S.aureus 
S.epidermidis 
S.faecalis 
S. pneumoniae 
S.pyogenes 
Morphine alone had no antimicrobial effects at 
the concentrations tested and had no synergistic 
antimicrobial effect with bupivacaine when 
tested in combination. 
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certain opioids may be related to their molecular weight, thermodynamic activity and 
pH rather than their chemical structure (48). 
 
2.5.3 Microbial contamination of fentanyl in particular 
 
Evidence suggests that fentanyl itself has no discernable antimicrobial 
properties(50,63). 
 
2.6 Microbial contamination of multi-dose containers 
 
2.6.1. Clinical use of multi-dose containers 
 
A true multi-dose vial is one which contains preservatives and, according to 
manufacturer’s specifications, may be used more than once (65).  However, at a time 
when cost containment in health care is increasingly important, many centres are 
looking to using single dose products for multiple patients (66).  The reasons for this 
are increased convenience, decreased environmental waste and presumed cost-
reduction (56,67), although some authors dispute whether this is indeed a cost-
saving practice (68).  Concern over microbial contamination of such products has 
prompted extensive investigation in the literature.  
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2.6.2. Risk of microbial contamination of multi-dose vials in clinical practice 
 
Many studies have investigated the risk of microbial contamination of multi-dose 
vials containing various different medications in clinical use.  In 1984, Longfield 
reviewed the subject and showed that previous studies had found 0 – 27% of multi-
dose vials in clinical use to be contaminated (67).  However, the authors of that 
review noted 90% of culture positive results had occurred before 1973 and suggested 
reasons for this being an evolution in preservatives used in multi-dose vials as well as 
a shift in drugs which were available in multi-dose formulations.  They also 
mentioned that the practice of using multi-dose diluents has largely been replaced by 
using single-unit substitutes.  In their synopsis of the eleven studies, only 24 of 4036 
vials tested were found to be contaminated.  When excluding multi-dose antibiotics or 
diluents, the authors estimated that the incidence of contamination of multiple dose 
vials is 0.28%.  A positive correlation was noted between contamination and number 
needle entries into the multi-dose vials (67).  In their own study, Longfield et al 
investigated the risk of contamination of various drugs used in clinical practice and 
found the incidence of contamination to be exceedingly small.  None of the 1223 
samples taken from various drugs in clinical use yielded positive microbial culture 
(67). 
 
Since Longfield’s review, several authors have examined the occurrence of microbial 
contamination of multi-dose vials containing various medications in clinical practice 
(57,64,66,69-74).  Contamination rates in these studies were found to be 0 – 12% 
(Table 2.6).  This considerable range can be accounted for in part by methodology and 
by the different agents investigated.  The study which showed the highest 
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contamination rate examined the sterility of opioids in syringes prepared and used 
for titration in a single patient (64).  In this study, the syringes came into direct 
contact with patients, which could account for the higher contamination rate.  In one 
study, no specific aseptic technique was used in withdrawal of medications from 
multi-dose vials and the contamination rate was found to be 5.6% (70).  However, in 
the studies which used multi-dose containers from which aliquots were withdrawn 
using aseptic technique and standard infection control precautions, the 
contamination rate was found to be very low at 0 – 0.88% (57,64,66,69,71-74).  
 
In one study, the investigators matched 265 vials of medication in clinical use with 
vials containing culture broth (71).  These matched vials were submitted to the same 
clinical handling and storage as the vials in clinical practice over a period of time.  
None of the 265 vials of broth yielded any microbial growth on culture.  Since broth 
would allow growth of any pathogen which had been introduced into the vial during 
clinical practice, this study gives staunch support to the notion that microbial 
contamination of multi-dose containers in clinical practice is exceedingly rare.  A 
logical extension would be that the risk of contamination would be further decreased 
if the agent contained in the multi-dose vial possessed inherent antimicrobial 
properties (66), such as in the case of bupivacaine.  It has, however, been noted that 
the risk of microbial contamination depends not only on the nature of the medication 
being prepared, but also on the aseptic technique of the health practitioner carrying 
out the preparation (70,72). 
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Table 2.6: Summary of investigations into microbial contamination of multi-dose vials in clinical use 
AUTHOR DRUGS 
INVESTIGATED 
SAMPLE 
SIZE 
METHODOLOGY OUTCOME 
Chen 
(2009)  
 
(69) 
Bevacizumab 
(recombinant anti-
VEGF antibody) 
12 
 
4 – 5 aliquots were drawn out of a multi-dose vials for clinical use 
using aseptic technique.  The remaining contents were left in vials & 
refrigerated for 1, 2 & 6 months, at which times microbiological 
samples were taken. 
No microbial contamination was detected. 
Motamedifar 
(2009)  
(70) 
Medications of 
various types in 
clinical use 
637 
 
All multi-dose vials used clinically in a hospital over a 4-month 
period were collected at tested for aerobic bacteria. 
5.6%  (38 samples) were found to be 
contaminated 
 
Murray 
(2005)  
 
(71) 
Sterile radio-
pharmaceuticals with 
long shelf lives 
265 
 
Vials of drug were matched with vials of culture broth.  The broth 
accompanied the clinical vial throughout its time in use.  When an 
aliquot was withdrawn for clinical use, a sample of broth was 
withdrawn & sent for microbiological investigation.  
No microbial contamination was detected. 
Mattner  
(2004) 
 
 (72) 
Medications of 
various types in 
clinical use 
 
227  
 
On a single day, all opened vials and syringes intended for multiple 
dosing were collected from all wards in a hospital.  Samples were 
withdrawn under aseptic conditions and cultured on blood agar and 
thioglycollate broth. 
 0.88% (2 samples) were found to be 
contaminated. 
Taylor  
(1997)  
 
 
(64) 
Pethidine & Morphine 
 
100 
 
Opioids which had been prepared in syringes, each used to titrate 
opioids in the same patient, were submitted for microbiological 
investigation.  Half of the syringes were prepared in the Emergency 
Room and half under aseptic conditions in the pharmacy. 
 12% of the syringes were found to be 
contaminated, with equal numbers  
contaminated from those prepared in the 
Emergency Room and Pharmacy.  
Green 
(1995) 
 (66) 
Gadolinium MR 
contrast medium 
15 
 
The residual contrast medium of single-dose vials that had been 
used for multiple patients were submitted for microbiological 
investigation. 
No microbial contamination was detected. 
Christensen 
(1992)     (73)  
Lyophylized virus 
vaccine 
200 
 
Empty vials which had been used in clinics were tested for microbial 
contamination.  
No microbial contamination was detected. 
Longfield 
(1985)     (57) 
Various medications 
in clinical use 
1223 1223 weekly samples were cultured from 864 multi-dose vials in 
clinical use. 
No microbial contamination was detected. 
Rathod 
(1985) 
 (74) 
Insulin 
 
69 
 
Vials of insulin in clinical use were submitted for microbial 
investigation. 
 
8 (11.6%) samples showed microbial 
contamination. 5 were re-cultured after 24 
hours yielded no microbial growth. 
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2.6.3. Clinical implications of contamination  
 
Despite this very low risk of contamination, there have been case reports in the 
literature of outbreaks of various infections which can be traced to contamination of 
multi-dose vials (56,75).  Mattner quotes 17 such reports, which include accounts of 
bacterial and protozoan contamination (72).  The same authors quote newspaper 
reports of two deaths caused by intrathecal administration of contrast media 
contaminated by P. aeruginosa (72).  On the other hand, one investigation into the 
clinical relevance of microbial contamination of opioids found that, although 12% 
syringes prepared for titration of opioids showed microbial contamination, this 
resulted in no contribution to patient morbidity or mortality (64).  This study was 
investigating the risk of intravenous rather than intrathecal administration of 
contaminated agents, and the patients were all immunocompetent.  The findings may 
have been different had the administration been via the intrathecal route or to 
immunocompromised patients. 
 
Whilst the literature presents a wide range of evidence, it seems that the overall risk 
of contamination of multi-dose vials is exceedingly low when aseptic technique is 
employed in handling of these vials and when the vials are stored in the correct 
manner.  However, there have been cases of microbial contamination reported and 
some of these have had severe clinical sequelae.  Some authors have indicated that, 
although the risk of microbial contamination of multi-dose vials may be rare, it would 
still seem prudent to use single-dose containers for each patient (70,76).  
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2.7 Overall conclusions from the literature 
 
Never before has there been a study conducted to ascertain the extent of risk of 
microbial contamination associated with the drug mixture described in Appendix A. 
Related previous studies have suggested that infectious complications following 
spinal anaesthesia are rare.  In order to minimise even this small risk, previous 
authors have cautioned against the use of multi-dose vials for intrathecal agents.  
However, it would appear that the risk of contamination of multi-dose vials in general 
is exceedingly low.  This, combined with some antimicrobial effect of bupivacaine, 
makes the risk of microbial contamination, survival and proliferation in the drug 
mixture to be studied seem to be very small indeed.  
 
However, the addition of dextrose as a source of nutrition and the fact that 
bupivacaine has not been shown to have universal antimicrobial properties is 
concerning.  Of prime concern are the potentially catastrophic sequelae in the event 
of infections related to spinal anaesthesia.   
34 
 
CHAPTER 3: MATERIALS AND METHODS 
 
This chapter details the materials and methods used for the current pilot study. 
 
3.1 Location 
 
The study was carried out in one of the obstetric theatres at Chris Hani Baragwanath 
Hospital (CHBH), Johannesburg.  These operating theatres service the labour ward at 
CHBH, which functions as the tertiary referral centre for the greater population of 
Soweto, Johannesburg and surrounding areas.  Patients are referred from 
surrounding primary and secondary health facilities for complicated pregnancies and 
labours.  There are approximately 1800 deliveries per month and a 30% caesarean 
section rate in this Department (77).  The average number of caesarean sections 
carried out in the Obstetric Theatres over an 18 month period starting from January 
2008 was 608 per month (77). 
 
3.2 Permissions 
 
The protocol for this study was submitted to the Human Research Ethics Committee 
(Medical) at the University of the Witwatersrand and was granted an Ethics Waiver 
(Appendix B).   It was also submitted to the Faculty of Health Sciences Post Graduate 
Committee at the University of Witwatersrand, which granted permission to continue 
with the study (Appendix C), as well as to the Medical Superindendent of Chris Hani 
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Baragwanath Hospital (CHBH), who likewise gave permission for the study to be 
carried out on the premises of CHBH (Appendix D). 
 
3.3 Research Methodology 
 
3.3.1 Research Design 
This investigation is a prospective and longitudinal observational pilot study. 
Prospective: Data which are to be studied are yet to be generated 
Longitudinal:  The study will be carried out over time and chronological time will 
   have the opportunity to exert an effect on the variables 
Pilot study: A small-scale study conducted in order to check feasibility or  
   improve on study design prior to initiation of the main study 
 
3.3.2 Study population and study sample 
 
3.3.2.1 Study Population 
The study population was a mixture of hyperbaric bupivacaine and fentanyl prepared 
by the investigator at Chris Hani Baragwaneth Hospital, according to a protocol at 
that hospital (Appendix A).  Syringes prepared according to this protocol were 
allocated to pairs.  Each pair had one syringe from which only two samples were 
drawn, one at the beginning and one at the end of the study period, referred to from 
here on as the control syringe.  The other syringe in the pair was sampled each hour 
during the study period and is referred to as the multi-dose syringe.  
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3.3.2.2 Study sample 
As an investigation of this nature has never been done before, it was decided to first 
perform a pilot study in order to assess methodology and final sample numbers 
needed to adequately power a future study.  It was decided that submission of 100 
samples for microbiological investigation would give sufficient opportunity for this 
assessment. Since each syringe pair yields six samples for microbiological 
investigation, it was decided that the pilot study should utilise twenty syringe pairs.  
It was anticipated that there would be very few, if any, contaminated syringes, and 
therefore it is unlikely that this sample size would be sufficient for a final study with 
sufficient power to generate significant results.  However, the results from the pilot 
study would be able to inform the sample size required for such a future study. 
 
3.4 Procedure for Data Collection 
 
3.4.1 General Procedure 
 
It has been previously shown that anaesthetic work areas are quickly contaminated 
by microbes (78).  It is therefore important to assess possible microbial 
contamination in the theatre setting, as opposed to a laboratory setting.  Therefore, 
during the study period, the investigator worked in an obstetric theatre whilst cases 
were being done, in an attempt to carry out this study in a situation which mirrors the 
clinical setting as closely as possible.  During the study period, however, the 
investigator was in no way responsible for the anaesthetic care of any of the patients 
in the theatre.  This was so as to ensure that the study had no negative impact upon 
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patient care in the obstetric theatres.  Furthermore, the drug mixture in the syringes 
under investigation was not administered to any patients during the study period. 
 
3.4.1.1 Preparations prior to commencement of the study period 
The literature has an account of a local anaesthetic similar to bupivacaine 
(ropivacaine) causing turbidity of a growth medium similar to thioglycollate 
(Mueller-Hinton broth) as a result of precipitation rather than microbial 
contamination (14).  In order to ensure that this was not the case using bupivacaine 
with thioglycollate broth, one tube of thioglycollate was inoculated with 1,5ml of the 
drug mixture under investigation and observed for turbidity.  None was noted after 
10 days at room temperature and it was concluded that any turbidity of the broth 
could be attributed to microbial contamination and not precipitation due to chemical 
reaction. 
 
Prior to the commencement of each study period, the technicians at the National 
Health Laboratory Service (NHLS) laboratory at CHBH placed the required number of 
tubes containing thioglycollate broth into an aerobic incubator for 48 hours.  This was 
to ensure that none of the tubes containing this growth medium were contaminated 
by microbial growth prior to inoculation with study samples.  It was agreed that, 
should any of the broth become turbid during this overnight incubation, it should be 
discarded. 
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3.4.1.2 Control of fentanyl 
Fentanyl is a Schedule Six drug and therefore it is required by law that this drug be 
controlled (79).  After delivery by Fresenius-Kabi to the investigator, the fentanyl for 
this study was counted and signed off by the investigator and a senior consultant in 
the Department of Anaesthesia at CHBH.  The fentanyl stock was then kept in the 
locked obstetric theatre drug cupboard separate from that in clinical use.  A Schedule 
Six drug register was kept against the invoice from Fresenius-Kabi, with the Sister-in-
Charge of obstetric theatre signing for the initial receipt from the investigator of 
eighty ampoules of fentanyl 100 μg.2ml-1.  Thereafter, sufficient ampoules for each 
study period were issued to the investigator upon signature.  At each issuing, one of 
the anaesthetic nurses signed as the “controller” and the investigator co-signed as the 
“administrator” of the drugs.  The study numbers which were assigned to each 
syringe were used instead of the patient’s name in the register, and two ampoules 
were signed off for each syringe as per the protocol below.  On three occasions during 
the study, the stock of fentanyl was counted and signed off by a Chief Professional 
Nurse.  At the end of the study period there was no remaining fentanyl.  Certified 
copies of the Scheduled Substance register were made, with the original being kept in 
the Department of Anaesthesia and copies being held by the investigator and 
supervisor. 
 
3.4.1.3 General procedure during data collection 
At the beginning of the twelve-hour study period, the investigator prepared two 
syringes containing the same mixture of hyperbaric bupivacaine and fentanyl, in 
accordance with the Departmental Protocol, Option 2 using fentanyl 200μg 
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(Appendix A).  Both these syringes remained in the theatre for the full twelve-hour 
study period. When not being sampled, the syringes were capped using a sheathed 
hypodermic needle.  Each pair of syringes was assigned a study number (MIC 001- 
MIC 020), with one syringe from each pair being designated as the control syringe 
(“CS”) and the other the multi-dose syringe (“MS”).  
 
For purposes of clarity, volumes withdrawn from the syringes which were sent to the 
laboratory as specimens are referred to as “samples” whilst those discarded are 
referred to as “aliquots.” 
 
A 1,5ml sample from the drug mixture in the control syringe was withdrawn at Time = 
0 hours, which was within 15 minutes of the preparation of the drug mixture in the 
syringe.  A second 1,5ml sample was withdrawn twelve hours later (T = 12 hours).  
These two samples were each transferred immediately to thioglycollate broth using 
standard aseptic technique, labelled CS-00 and CS-12 respectively, and taken to the 
microbiology laboratory for investigation in accordance with the protocol outlined 
below.  
 
This study required a growth medium which would be non-selective and would yield 
growth even with a very small initial inoculum of microbes.  For these reasons, we 
selected thioglycollate broth as the growth medium.  This is an all-purpose growth 
medium which is useful in isolating a wide range of organisms, including aerobic and 
anaerobic bacteria and yeasts, and is good a yielding recovery from low numbers of 
microbes in the initial inoculum (68,80). 
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A 1,5ml sample from the drug mixture in the multi-dose syringe was withdrawn at 
Time = 0 hours, which was within 15 minutes of the preparation of the drug mixture 
in the syringe.  Further 1,5ml samples were withdrawn at Time = 4, 8, and 12 hours.  
Each of these samples were immediately transferred into thioglycollate broth, 
labelled MS-00, MS-04, MS-08 and MS-12 respectively, and taken to the microbiology 
laboratory for investigation in accordance with the protocol outlined below.  In 
addition to these samples, 1,0ml aliquots were withdrawn each hour where a sample 
was not being withdrawn (i.e.: Time = 1,2,3,5,6,7,9,10 and 11 hours).  These 1,0ml 
aliquots were discarded immediately after withdrawal.  The intention of the 
withdrawal of these aliquots was to approximate the clinical situation in the obstetric 
theatres at CHBH, where caesarean sections performed approximately hourly. 
 
During the study period, theatre temperatures were measured hourly using a digital 
thermometer.  A record was kept of the following parameters on a Data Sheet 
(Appendix E). 
a) Sample numbers 
b) Corresponding NHLS bar code and NHLS laboratory numbers 
c) Time syringes were prepared 
d) Time the samples reached the laboratory 
e) Times the samples were placed in the incubator 
f) Theatre temperatures at the time that the samples were taken 
g) Number of cases done during the study period 
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3.4.2 Labelling of samples 
 
All samples in thioglycollate broth tubes were labelled with a unique study number 
printed on a self-adhesive label.  This number allowed identification of a) the syringe 
pair (001 in the example below), b) whether it was withdrawn from the control or the 
multi-dose syringe (CS for control syringe in the example below) and c) the time 
during the study period at which the sample was taken (Time = 0 hours in the 
example below).  
Example of a study number: 
MIC 001 – CS – 00 
 
In addition to the unique study number, the detachable barcode from the National 
Health Laboratory Service (NHLS) request form was affixed to the sample bottle.  A 
record of this barcode was kept along with the unique sample number for ease of 
recovery of results from the laboratory system. 
 
 3.4.3 Preparation of drug mixtures 
 
The method for preparation of drug mixtures was designed so as to mimic the clinical 
situation as closely as possible.  Drug mixtures were prepared by the investigator 
only in the obstetric theatre at CHBH.  Hands were washed using chlorhexidine hand 
scrub prior to preparation of the drug mixtures, but no gloves or facemask were 
worn.  In accordance with the protocol used at CHBH (Appendix A), four ampoules of 
Micro Bupivacaine Spinal with Dextrose Injection (Micro Healthcare, Pty, Ltd), each 
containing 4ml volume, were drawn up into a newly-opened sterile 20ml syringe 
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(BBraun Medical, Pty, Ltd) using a newly-opened sterile 22 gauge hypodermic needle 
(BBraun Medical, Pty, Ltd).  Two ampoules of Fentanyl-Fresenius (Fresenius Kabi 
South Africa, Pty, Ltd), each containing 100 μg, were then drawn into the same 20ml 
syringe using the same hypodermic needle.  The resulting drug mixture comprised 
fentanyl 10 μg.ml-1, bupivacaine 4mg.ml-1 and dextrose 64mg.ml-1 with a total volume 
of 20ml.  
 
The syringes were then left on a trolley in the obstetric theatre for the following 
twelve hours and remained capped with the original 22 gauge needles at all times 
except for when samples and other aliquots were being withdrawn.  This was applied 
regardless of other activity in the theatre (i.e.: theatre being empty, cases being done 
or theatre being scrubbed down between cases). 
 
3.4.4 Withdrawal of samples and other aliquots 
 
In clinical practice, according to the protocol in Appendix A, once a syringe has been 
prepared with the drug mixture described above, aliquots are withdrawn using newly 
opened sterile syringes for administration in obstetric spinal anaesthesia.  With an 
average of over 600 caesarean sections per monthat CHBH (77), hourly sampling 
seemed a reasonable estimate of clinical sampling frequency.  
 
Prior to the withdrawal of samples intended for microbiological processing, the 
investigator labelled a tube of thioglycollate broth with a unique sample number 
previously described, as well as a barcode which linked the sample to the laboratory 
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request form.  The thioglycollate tube was then laid upon the corresponding 
laboratory request form. 
 
In preparation for the withdrawal of all aliquots, the investigator donned a standard 
surgical mask and opened a sterile pack containing a lotion cloth and hand towels on 
a stainless steel trolley in the obstetric theatre.  Onto the sterile lotion cloth, a pack of 
sterile gloves (Biogel Skinsense ®, Mölnlycke Healthcare, Sweden), a sterile 5ml 
syringe (Omnifix®, BBraun Medical, Pty, Ltd) and a sterile 22 gauge hypodermic 
needle (Sterican®, BBraun Medical, Pty, Ltd) was opened for each sample to be taken.  
All packs were opened in an aseptic manner.  The control and multi-dose syringes 
from which samples were to be taken were then shaken.  The capping hypodermic 
needle on each syringe was removed and laid next to the syringe.  The syringes were 
positioned under the edge of the lotion cloth to enable the investigator to with draw 
the sample whilst maintaining asepsis. 
 
Whilst still wearing the surgical mask, the investigator performed a surgical hand 
scrub using a 4% chlorhexidine gluconate skin cleanser (BioscrubTM, Dismed Pharma, 
Pty, Ltd).  Forearms were scrubbed up to the elbows and hands were washed 
according to the hand washing protocol used at CHBH (81).  This procedure was 
carried out three times.  Hands were then dried on the sterile hand towels and the 
sterile gloves were donned.  If, for any reason the gloved hands touched a non-sterile 
object (e.g.: when samples were being withdrawn from control and multi-dose 
syringes during the same sampling period), the potentially contaminated gloves were 
discarded, hands were re-scrubbed as per the above procedure and a new pair of 
sterile gloves were donned. 
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The hypodermic needle which had been opened onto the sterile cloth was then 
attached to the 5ml syringe.  Whilst holding the 20ml control or multi-dose syringe 
through the sterile lotion cloth, the investigator withdrew a 1,5ml sample for 
microbiological processing or a 1,0ml aliquot to be discarded, as dictated by the 
abovementioned protocol.   
 
3.4.5 Transfer of sample to growth medium 
 
The syringe containing the sample was held in the investigator’s right hand.  The 
thioglycollate tube into which the sample was to be transferred was then picked up in 
the left hand.  The little finger of the right hand was used to remove the lid of the 
thioglycollate tube as per standard aseptic technique, taking care not to touch the 
under surface of the lid.  Then, without letting the hypodermic needle touch the sides 
of the tube, the sample was expressed into the thioglycollate broth.  The lid was 
immediately replaced using only the little finger, and care was taken to ensure that it 
fitted snugly. 
 
3.4.6 Disposal of sampling materials 
 
After each sample was withdrawn, the used gloves and syringes were discarded into 
the appropriate medical waste bin.  The 5ml syringes containing the aliquots from the 
multi-dose syringes which were not intended for microbiological investigation were 
also discarded in this manner.  All needles were discarded in the sharps containers 
available.  
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3.4.7 Transport of the samples to the microbiological laboratory 
 
Once the labelling of the samples had been carefully checked, the investigator 
personally transferred both the tubes of thioglycollate broth containing the samples 
together with the corresponding NHLS request forms to the NHLS laboratory at 
CHBH. Upon arrival at the laboratory, the request forms were franked to indicate time 
of arrival at the laboratory.  The staff in the reception of the laboratory then logged 
the samples onto the NHLS computer system and made two copies of the request 
forms.  The original request form was kept at the laboratory reception, with one of 
the copy being sent to the Department of Microbiology and the other remaining with 
the investigator for study records.  The investigator then personally placed the 
samples on a rack in a walk-in aerobic incubator within thirty minutes of the sample 
being withdrawn.  
 
3.4.8 Microbiological processing of samples 
 
Processing of the samples in the laboratory was according to NHLS Standard 
Operating Procedures (80). The tubes of inoculated thioglycollate broth were 
incubated aerobically at 37 °C and examined daily for turbidity by the microbiology 
technicians.  Turbid samples were sub-cultured onto 5% sheep blood agar using a 
sterile wire loop.  The agar plates were then incubated for a further 24 hours at 37 °C 
and examined for any microbial growth by qualified laboratory technicians using 
standard techniques.  For logistical purposes, the technicians knew that the samples 
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were being investigated as part of a sterility study.  However, they were not informed 
of the significance of sample labels. 
 
The sample was considered to be positive for microbial growth as defined by 
turbidity of the thioglycollate broth with subsequent growth of any microorganism 
demonstrated on the blood agar.  In the event of any microbial growth on the sheep 
blood agar, the organism(s) were further identified by a microbiologist.  If a Viridans 
group Streptococcus or a Coagulase-negative Staphylococcus was identified, then 
further speciation was carried out using an automated process.  When the inoculated 
thioglycollate broth remained clear after 48 hours in the incubator, the sample was be 
considered to be sterile and discarded according to laboratory protocol. 
 
3.4.9 Recording of temperature 
 
The effect of differences in temperature is important to note since we are examining 
the potential contamination of syringes kept in the theatre environment at room 
temperature, and it may be inappropriate to assume that previous investigations into 
the antimicrobial properties of bupivacaine at higher temperatures may be 
extrapolated to the environment of the current study (see 2.3.6).  Therefore, a record 
was kept of theatre temperatures during the study period.  Each hour during the 
study period, the theatre air temperature was recorded using a digital thermometer 
(Flash Check Pocket Probe Thermometer, DeltaTRAK ®, Inc, USA).  The thermometer 
was strapped to the leg of the trolley on which the test syringes were kept with 
hourly recordings made in degrees Celsius.  According to the manufacturers, this 
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thermometer has an accuracy of ± 0,5°C in the temperature range of -20°C to 90°C, 
which suited the purposes of this study. 
 
3.4.10 Recording the of number of cases 
 
The number of cases done during each study period was recorded as per the theatre 
register in an attempt to estimate theatre traffic, which was hypothesised may 
contribute to contamination of the syringes. All types of operation were included in 
the count of operations.  Any case which was in progress during the study period was 
included, even if it had begun prior to the start of the study period or continued after 
the end of the study period.  
 
3.5 Inclusion & exclusion criteria 
 
3.5.1 Inclusion criteria 
 
Samples taken in the prescribed manner from drug mixtures prepared by the 
investigator according to the existing protocol (Appendix A, Option 2 using 200μg 
fentanyl) for the purpose of this study were included. 
 
3.5.2 Exclusion criteria 
 
Prior to commencement of the study, it was decided that samples would be excluded 
from the study under the following circumstances: 
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3.5.2.1 Samples which reached the aerobic incubator in the NHLS laboratory greater 
 than 30 minutes after withdrawal from the multi-dose or control syringe 
3.5.2.2 Samples in containers which were damaged during transport 
3.5.2.3 Samples from syringes which were inadvertently left uncapped between 
 samplings 
3.5.2.4 Samples from syringes which were inadvertently removed from the operating 
 theatre during the study period 
3.5.2.5 Any breach of aseptic technique during the withdrawal of aliquots 
 
3.6 General procedure for obtaining of results 
 
According to the protocol for microbiological processing, results of the 
microbiological investigation were available within 72 hours of the sample reaching 
the laboratory.  The staff of the results office printed hard copies of the laboratory 
reports, which were collected by the investigator.  Results were then recorded on the 
data sheet (Appendix E).  Microbial contamination was recorded as categorical data 
with 0 indicating no growth and 1 indicating growth.  Quantitative data collected 
during the study periods was entered and note was made of species identification of 
samples which yielded microbial growth.  
 
 
 
 
 
49 
 
3.7 Data analysis 
 
3.7.1 Analysis of primary outcome 
 
Data for the primary outcome was considered as categorical data, i.e. the presence or 
absence of contamination of the samples.  Descriptive statistics were presented as 
percentages of samples found to be contaminated.  The comparison between multi-
dose and control syringes was then used to calculate the sample size which will be 
required for statistical significance using a two-tailed calculation. 
 
3.7.2 Analysis of secondary outcomes  
 
Data for secondary outcomes, namely temperature variation in the theatres and 
number of cases done, were presented as quantitative data with respect to time.  The 
means and standard deviations of these data were presented for each day and for 
each study period.  Statistical analysis was performed using Microsoft Excel 2007. 
 
3.8 Funding 
 
Funding for this project was obtained from the Faculty of Health Sciences. 
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3.9 Summary of materials and methodology used 
 
This chapter has detailed where this pilot study took place, the nature of the study 
design, and the materials and methodology which were used.  The protocols for data 
collection, inclusion and analysis have also been presented. 
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CHAPTER 4: RESULTS 
 
In this chapter, results are presented for both Primary and Secondary outcomes for 
this study. 
 
4.1 Inclusion of samples 
 
4.1.1 Number of samples taken 
 
Twenty syringe pairs were studied.  Four samples were taken from each multi-dose 
syringe and two from each control syringe.  
 
4.1.2 Time period 
 
The study was carried out over a period of five days, on 23 November, 30 November 
and 1 – 3 December 2009.  Samples from all twenty syringe pairs were collected on 
these days.  Two syringe pairs were prepared simultaneously with the initial samples 
drawn and taken to the incubator in the NHLS laboratory.  The next two syringe pairs 
were then prepared an hour later.  A maximum of six syringe pairs were processes in 
any single day.  Table 4.1 summarises the dates and times of the twelve-hour study 
period for each syringe pair. 
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Table 4.1: Temporal relationships of study periods for each syringe pair 
 
 
4.1.3 Exclusion of sample 
 
During transfer of one sample (MIC-006-CS-12) to the thioglycollate broth, the inside 
of the receiving tube was inadvertently touched with the needle being used for 
inoculation.  Aseptic technique was deemed to have been breached, and this sample 
was excluded. Since it was one of the samples taken at Time = 12 hours from a control 
syringe, the remainder of the samples drawn from that particular syringe pair were 
included in the study.  This left 119 eligible samples belonging to twenty syringe 
pairs.  
 
  
SYRINGE 
PAIR 
DAY NUMBER OF 
STUDY 
DATE OF DATA 
COLLECTION 
STARTING TIME 
OF DATA 
COLLECTION 
END TIME OF 
DATA 
COLLECTION 
MIC-001 1 23 November 2009 06h30 18h30 
MIC-002 1 23 November 2009 06h30 18h30 
MIC-003 2 30 November 2009 05h30 17h30 
MIC-004 2 30 November 2009 05h30 17h30 
MIC-005 2 30 November 2009 06h30 18h30 
MIC-006 2 30 November 2009 06h30 18h30 
MIC-007 3 1 December 2009 04h30 16h30 
MIC-008 3 1 December 2009 04h30 16h30 
MIC-009 3 1 December 2009 05h30 17h30 
MIC-010 3 1 December 2009 05h30 17h30 
MIC-011 3 1 December 2009 06h30 18h30 
MIC-012 3 1 December 2009 06h30 18h30 
MIC-013 4 2 December 2009 04h30 16h30 
MIC-014 4 2 December 2009 04h30 16h30 
MIC-015 4 2 December 2009 05h30 17h30 
MIC-016 4 2 December 2009 05h30 17h30 
MIC-017 5 3 December 2009 04h30 16h30 
MIC-018 5 3 December 2009 04h30 16h30 
MIC-019 5 3 December 2009 05h30 17h30 
MIC-020 5 3 December 2009 05h30 17h30 
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4.1.4 Adherence to protocol 
 
Table 4.2 indicates the time taken from withdrawal of each sample until the sample 
was placed in the incubator.  As per the protocol, all samples which were presented 
for microbiological investigation reached the incubator in the microbiological 
laboratory  
 
Table 4.2: Time in minutes from sample withdrawal to placement in incubator 
 
 CS-00 MS-00 MS-04 MS-08 MS-12 CS-12 
MIC-001 24 21 16 21 30 27 
MIC-002 19 17 14 19 24 21 
MIC-003 18 14 19 14 18 15 
MIC-004 7 10 22 18 11 8 
MIC-005 16 14 19 17 15 12 
MIC-006 11 8 17 13 9 Excluded 
MIC-007 19 16 20 20 18 22 
MIC-008 12 8 16 17 11 14 
MIC-009 19 16 26 23 24 21 
MIC-010 12 9 22 19 18 15 
MIC-011 20 17 12 17 24 21 
MIC-012 13 10 17 14 17 14 
MIC-013 19 15 19 12 24 20 
MIC-014 12 8 10 8 16 16 
MIC-015 29 24 19 19 28 25 
MIC-016 20 16 15 15 19 16 
MIC-017 26 20 11 12 24 27 
MIC-018 15 8 8 9 21 17 
MIC-019 26 23 20 19 21 19 
MIC-020 19 16 16 16 28 24 
 
CS-00 & CS-12 were samples taken from the control syringes at 0 and 12 hours respectively 
MS-00, MS-04, MS-08 and MS-12 were samples taken from the multi-dose syringes at 0, 4, 8 and 12 hours respectively 
MIC-001 through MIC- 020 correspond to the 20 syringe pairs investigated 
All times are presented in minutes 
 
 
within 30 minutes (mean = 17 minutes, range = 7 to 30 minutes) and no further 
specimen had to be excluded under this criterion.  Likewise, no sample containers 
were damaged during transport and no syringes were inadvertently left uncapped or 
removed from the theatre. 
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4.2 Primary Outcome Results: Microbiology 
 
4.2.1 Processing of microbiological results 
 
Hardcopy of results for all samples presented to the laboratory were obtained.  All 
samples presented to the laboratory had been processed as per the previously 
detailed protocol.  
 
4.2.2 Microbiological findings 
 
One sample of 119 presented for microbiological investigation yielded microbial 
growth after 48 hours of observation.  The sample (MIC-007-MS-00), which was a 
sample from a multi-dose syringe withdrawn at the beginning of a study period, 
yielded growth of Staphylococcus aureus.  
 
4.2.3 Data analysis in the microbiological investigation 
 
4.2.3.1 Description of data 
When considering all samples presented for microbiological investigation, 1 of 119 
samples (0.84%) yielded a positive culture.  However, in order to facilitate further 
calculations, the same data may be considered in terms of two groups, namely the 
multi-dose and the control syringes.  In this case, 1 of the 20 multi-dose syringes (5%) 
yielded a contaminated sample, whilst none of the 20 control syringes (0%) yielded a 
contaminated sample.   
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4.2.3.2 Calculation of sample size required 
In order to prove that contamination never occurs, an infinite sample would be 
required.  However, to prove statistically that there is a difference in contamination 
rates of at least 5% between the two groups, a sample size of n = 581 syringes in each 
group would be required using a two-tailed test (α = 0.05 and β= 0.10). 
 
4.3 Secondary Outcome Results:  Theatre temperatures 
 
4.3.1 Recording of theatre temperatures 
 
Theatre temperatures were measured using a digital thermometer every hour during 
the daily study periods listed in Table 4.1.  A record was kept of these measurements 
and presented in Table 4.3 according to the times of each day of the study period, as 
 
 
Table 4.3: Temperatures recorded on each day of investigation in ° C, showing mean and standard 
deviation (SD) for the temperatures on each day 
TIME DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 
04:30   22,6 22,9 22,6 
05:30  23,2 22,4 22,9 22,4 
06:30 23,0 23,2 22,6 22,6 22,7 
07:30 23,0 23,4 23,2 22,9 22,4 
08:30 23,3 23,5 23,6 23,1 23,2 
09:30 24,0 24,0 23,9 23,2 23,4 
10:30 24,2 24,4 24,1 23,2 23,6 
11:30 25,2 25,0 23,5 23,3 23,7 
12:30 25,2 25,2 23,9 23,6 23,7 
13:30 26,2 25,2 23,9 24,2 23,7 
14:30 26,0 25,7 23,5 23,7 24,2 
15:30 26,2 26,2 24,2 24,1 24,3 
16:30 25,9 26,4 24,2 23,2 24,2 
17:30 25,7 26,2 24,1 23,2 23,7 
18:30 25,4 24,9 23,8   
Mean (SD) 24,9 (1,2) 24,8 (1,2) 23,6 (0,6) 23,3 (0,5) 23,4 (0,7) 
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referred to in Table 4.1.  In order to facilitate the comparison of temperatures 
between corresponding study periods for each syringe pair, the same data is 
presented in Table 4.4 according to syringe pair. 
 
4.3.2 Data analysis of theatre temperatures 
 
Temperatures varied according to time of day, with temperatures generally being 
lowest in the morning, reaching a peak in late afternoon, and then subsiding.  Since 
the study periods were all commenced between 04h30 and 06h30 and extended for 
twelve hours (Table 4.1), the temperature profiles of the study periods closely 
resembled those of the diurnal variation.  However, the range of temperatures within 
corresponding sample times for each syringe pair was as much as 3,0° C (Table 4.4).   
 
 
 
Figure 4.1: Line graph of daily theatre temperatures 
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Table 4.4:  Theatre temperatures (°C) according to study periods 
 
T = 0 through T = 12 indicate time at 0 through 12 hours respectively 
MIC-001 through MIC- 020 correspond to the 20 syringe pairs investigated 
Range = range of temperatures for corresponding times across study periods 
SD = standard deviation 
All temperatures quoted in degrees Celsius 
  t = 0 t = 1 t = 2 t = 3 t = 4 t = 5 t = 6 t = 7 t = 8 t = 9 t = 10 t = 11 t = 12 
MIC-001 23,0 23,0 23,3 24,0 24,2 25,2 25,2 26,2 26,0 26,2 25,9 25,7 25,4 
MIC-002 23,0 23,0 23,3 24,0 24,2 25,2 25,2 26,2 26,0 26,2 25,9 25,7 25,4 
MIC-003 23,2 23,2 23,4 23,5 24,0 24,4 25,0 25,2 25,2 25,7 26,2 26,4 26,2 
MIC-004 23,2 23,2 23,4 23,5 24,0 24,4 25,0 25,2 25,2 25,7 26,2 26,4 26,2 
MIC-005 23,2 23,4 23,5 24,0 24,4 25,0 25,2 25,2 25,7 26,2 26,4 26,2 24,9 
MIC-006 23,2 23,4 23,5 24,0 24,4 25,0 25,2 25,2 25,7 26,2 26,4 26,2 24,9 
MIC-007 22,6 22,4 22,6 23,2 23,6 23,9 24,1 23,5 23,9 23,9 23,5 24,2 24,2 
MIC-008 22,6 22,4 22,6 23,2 23,6 23,9 24,1 23,5 23,9 23,9 23,5 24,2 24,2 
MIC-009 22,4 22,6 23,2 23,6 23,9 24,1 23,5 23,9 23,9 23,5 24,2 24,2 24,1 
MIC-010 22,4 22,6 23,2 23,6 23,9 24,1 23,5 23,9 23,9 23,5 24,2 24,2 24,1 
MIC-011 22,6 23,2 23,6 23,9 24,1 23,5 23,9 23,9 23,5 24,2 24,2 24,1 23,8 
MIC-012 22,6 23,2 23,6 23,9 24,1 23,5 23,9 23,9 23,5 24,2 24,2 24,1 23,8 
MIC-013 22,9 22,9 22,6 22,9 23,1 23,2 23,2 23,3 23,6 24,2 23,7 24,1 23,2 
MIC-014 22,9 22,9 22,6 22,9 23,1 23,2 23,2 23,3 23,6 24,2 23,7 24,1 23,2 
MIC-015 22,9 22,6 229 23,1 23,2 23,2 23,3 23,6 24,2 23,7 24,1 23,2 23,2 
MIC-016 22,9 22,6 22.9 23,1 23,2 23,2 23,3 23,6 24,2 23,7 24,1 23,2 23,2 
MIC-017 22,6 22,4 22,7 22,4 23,2 23,4 23,6 23,7 23,7 23,7 24,2 24,3 24,2 
MIC-018 22,6 22,4 22,7 22,4 23,2 23,4 23,6 23,7 23,7 23,7 24,2 24,3 24,2 
MIC-019 22,4 22,7 22,4 23,2 23,4 23,6 23,7 23,7 23,7 24,2 24,3 24,2 23,7 
MIC-020 22,4 22,7 22,4 23,2 23,4 23,6 23,7 23,7 23,7 24,2 24,3 24,2 23,7 
Range 0,8 1,0 1,2 1,6 1,3 2,0 2,0 2,9 2,5 2,7 2,9 3,2 3,0 
Mean 22,8 22,8 23,0 23,4 23,7 24,0 24,1 24,2 24,3 24,6 24,7 24,7 24,3 
SD 0,29 0,34 0,42 0,51 0,46 0,70 0,76 0,94 0,91 1,03 1,04 1,03 0,93 
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The sample which yielded microbial growth was taken at Time = 0 hours, when the 
theatre temperature was 22,6° C.  This is one of the lowest temperatures recorded (z 
score = -1,29).   
 
4.4 Secondary Outcome Results:  Numbers of cases done in theatre 
 
4.4.1 Recording of number of cases done in theatre during the study period 
 
Official case start and end times were extracted from the theatre register in the 
obstetric theatre on the days over which the study ran.  Start and end times for cases 
which were in progress during the study periods on each day referred to in Table 4.1  
were noted (Table 4.5).  These times were then used to determine the number of 
cases which had been commenced between when each syringe pair was prepared and 
the corresponding samples were withdrawn (Table 4.6). 
 
Table 4.5: Start and end times of all cases in progress during study periods on each day 
 
 
 
  
 DAY 1 DAY 2 DAY 3 DAY 4 DAY 5 
1ST CASE 09h15 – 09h50 09h20 – 10h00 04h10 – 05h00 09h10 – 10h20 05h05 – 05h30 
2ND CASE 10h10 – 11h15 10h40 – 11h20 05h30 – 06h30 10h30 – 11h20 Not recorded 
3RD CASE 11h30 – 12h10 12h15 – 12h50 08h15 – 09h10 11h30 – 12h15 09h30 – 10h10 
4TH CASE 12h30 – 13h50 13h15 – 14h15 09h25 – 10h00 13h00 – 13h50 10h25 – 11h25 
5TH CASE 14h45 – 15h45 14h35 – 15h25 11h15 – 12h15 14h35 – 15h05 11h50 – 12h55 
6TH CASE  16h45 – 17h45 12h40 – 13h50 16h15 – 17h20 13h50 – 14h40 
7TH CASE  18h00 – 20h20 17h00 – 17h50  15h35 – 16h10 
8TH CASE   18h15 – 19h45   
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4.4.2 Findings of investigation into number of cases done during the study period 
 
Within each corresponding sampling period, the number of cases which had been 
commenced was very similar.  In fact, the greatest range for any sampling period was 
3 cases (Table 4.6).   
 
Table 4.6: Number of cases performed between preparation of syringe pair and withdrawal of 
samples with the range for corresponding samples 
 
CS-00 & CS-12 were samples taken from the control syringes at 0 and 12 hours respectively 
MS-00, MS-04, MS-08 and MS-12 were samples taken from the multi-dose syringes at 0, 4, 8 and 12 hours respectively 
MIC-001 through MIC- 020 correspond to the 20 syringe pairs investigated 
 
 
4.5 Summary of findings 
 
One sample from one of the twenty multi-dose syringes yielded microbiological 
growth, which was identified as Staphylococcus aureus.  None of the control syringes 
 CS-00 MS-00 MS-04 MS-08 MS-12 CS-12 
MIC-001 0 0 1 4 4 5 
MIC-002 0 0 1 4 4 5 
MIC-003 0 0 1 4 6 6 
MIC-004 0 0 1 4 6 6 
MIC-005 0 0 1 5 7 7 
MIC-006 0 0 1 5 7 7 
MIC-007 1 1 2 5 6 6 
MIC-008 1 1 2 5 6 6 
MIC-009 0 0 1 4 5 5 
MIC-010 0 0 1 4 5 5 
MIC-011 1 1 2 4 5 5 
MIC-012 1 1 2 4 5 5 
MIC-013 0 0 0 3 6 6 
MIC-014 0 0 0 3 6 6 
MIC-015 0 0 1 4 6 6 
MIC-016 0 0 1 4 6 6 
MIC-017 0 0 2 5 7 7 
MIC-018 0 0 2 5 7 7 
MIC-019 1 1 2 5 7 7 
MIC-020 1 1 2 5 7 7 
Range 1 1 2 2 3 2 
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yielded growth.  In a future study, the sample size needed to confirm a difference in 
contamination rates between the two groups is 581 syringes in each group. 
 
Measurement of theatre temperatures indicated a consistent diurnal variation. 
However, there was considerable discrepancy between temperatures recorded for 
correlating times between the twelve-hour study periods.  The only sample which 
yielded microbial growth, however, was taken when the theatre was almost at the 
coldest temperature recorded during the study. 
 
The number of theatre cases commenced at each sampling time was recorded.  It was 
found that there was not a great variation in number of cases commenced for 
corresponding sampling times between twelve-hour study periods. 
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CHAPTER 5: DISCUSSION 
 
Various difficulties and limitations were encountered during the execution of this 
study and these will be discussed in this chapter.  Further, the legal implications of 
using the controlled substance, fentanyl, in a multi-dose syringe will be considered.  
The results of this pilot study will then be examined and, finally, suggestions will be 
made for future work in this area. 
 
5.1 Difficulties encountered 
 
Some unforeseen practical difficulties were encountered during the implementation 
of this pilot study.  It will be useful to make note of these difficulties for future 
research.  
 
5.1.1 Exclusion of one sample 
 
Whilst the greatest of care was taken to maintain asepsis at all times, a needle used to 
inoculate one sample was accidentally brushed against the inside of the thioglycollate 
tube as the sample was being transferred.  This was considered to constitute a breach 
in asepsis and the sample was discarded.  
 
  
62 
 
5.1.2 Difficulty in getting the samples into the incubator within 30 minutes 
 
Even though the NHLS laboratory at CHBH is within walking distance from the 
obstetric theatres, there were difficulties in negotiating the practicalities of 
transporting the sample to the laboratory, ensuring that the sample was properly 
logged onto the computerised system and then placed in the incubator within 30 
minutes of collection.  In order to mitigate this, an arrangement was made with the 
laboratory staff that the investigator placed the samples in the incubator before 
logging them onto the system.  
 
5.1.3 Time constraints and processing of multiple syringe pairs each day 
 
Due to external time constraints, it was necessary for more than one syringe pair to 
be investigated each day.  An arrangement was made to stagger the sampling 
intervals (as discussed in 4.1.2), which allowed all samples to be properly handled 
according to the protocol.  However, because of this, some of the secondary outcome 
data was lost as the time periods were overlapping. Ideally, only one syringe pair 
should be processed each day. 
 
5.2 Limitations of the study 
 
Since research of this nature has not been done before, this pilot study was designed 
in order to inform both study methodology and sample size needed for a future study.  
The design of the pilot study intentionally removed as many confounders as possible 
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in order to examine the question at hand.  However, in removing these variables, the 
clinical context in which the results of this study are applicable have been narrowed. 
 
5.2.1 This study was carried out by a single investigator 
 
Since anaesthetic personnel differ in their performance of aseptic technique (15), it is 
possible that the findings of this study were dependent upon the person carrying out 
the procedure.  Therefore results may not necessarily be able to be extrapolated to all 
anaesthetic personnel using this protocol. 
 
5.2.2 This study was carried out in a single theatre 
 
Microbial contamination of the syringes under investigation may depend upon 
general microbial colonisation of the theatre environment.  Therefore, the results 
obtained in this particular theatre may not be able to be extrapolated to other 
theatres.   
 
5.2.3 Each drug studied was supplied by a single manufacturer 
 
For practical purposes, the hyperbaric bupivacaine and fentanyl were acquired from 
MicroHealth Products and Fresenius-Kabi respectively.  Further, the ampoules of 
each of these drugs came from a single batch, respectively.  In order to be able to 
extrapolate the results further, the investigation should be carried out using the 
ampoules from multiple batches produced by different manufacturers. 
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5.2.4 Only one type of culture medium was used 
 
Thioglycollate broth is an all-purpose growth medium which is useful in isolating a 
wide range of organisms, including aerobic and anaerobic bacteria and yeasts, and is 
good a yielding recovery from low numbers of microbes in the initial inoculum 
(68,80).  This is the broth which is used in sterility testing under the NHLS laboratory 
protocols (80).   However, there are fastidious organisms which may require other 
speciality broths in order to grow.  It is possible that the extent of our positive results 
was limited by the decision to use only one broth type. 
 
5.2.5 Samples were sent to one laboratory only 
 
For practical purposes, the NHLS laboratory at Chris Hani Baragwanath Hospital was 
used to carry out microbiological investigation on the samples obtained during the 
study.  In order to avoid ambiguity in positive results, however, it would be beneficial 
to draw two samples at a time and send each to a different laboratory for 
investigation under the same protocol.  This would avoid the situation which 
occurred in this pilot study whereby conclusive interpretation of an ambiguous 
positive result became impossible.   
 
5.2.6 The samples were incubated in an aerobic incubator only 
 
Samples were processed according to the NHLS Standard Operating Procedures, 
which specifies incubation in an aerobic incubator (80).  There is a possibility that 
anaerobic organisms may not have grown because of this. 
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5.3 Discussion of results of investigation of microbiological 
contamination 
 
Of 119 samples submitted for microbiological investigation, one yielded growth of 
Staphylococcus aurues (S. aureus).  The sample which yielded this grown was taken at 
the beginning of a study period from a multi-dose syringe (Time = 0 hours). However, 
subsequent samples taken from the same syringe at Time = 4, 8 and 12 hours yielded 
no growth, either of S. aureus or any other microbe.  There are several possible 
explanations for these results.  These explanations will be considered in two 
categories: 1) why it was that one sample was found to be contaminated and 2) if one 
sample was contaminated, why it was that more samples were not found to be 
contaminated. 
 
5.3.1 Possible explanations of why one sample was found to be contaminated 
 
5.3.1.1 The possibility that this was true contamination of the syringe 
The first explanation for one sample having yielded microbial growth is that there 
was microbial contamination of the syringe under investigation at the time that the 
sample was taken.  It is assumed that if contamination was sufficient to yield a 
positive culture result, that this could be clinically significant.  Our literature review 
has suggested that bupivacaine is a potent antimicrobial, which is particularly 
effective against S. aureus (14,33,34,39,48-51,53,54).  If the S. aureus present in the 
first sample was subsequently killed by the bupivacaine, this would explain why 
subsequent samples from the same syringe were found to be sterile.  This explanation 
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would support guidelines published by various bodies (6,7,29), recommending 
opening a new ampoule of drug for each patient rather than keeping drugs drawn up 
in syringes in theatre for fear of microbial contamination.  Indeed, when taking into 
consideration the potentially devastating sequelae of introducing pathogens into the 
intrathecal space, the fact that one sample out of 119 yielded microbial growth is a 
concerning point.  
 
5.3.1.2 The possibility that this was a spurious result 
A second explanation for the growth of S. aureus in a single sample is that the 
contamination of the culture medium occurred at some stage before or after 
inoculation, rather than as a result of contamination of the contents of the syringe.  
Since the sample had been taken immediately after the preparation of the drug 
mixture, and subsequent samples drawn from the same culture medium yielded no 
microbial growth, this would seem plausible.  Previous authors have found spurious 
positive cultures to be caused by specimen contamination, environmental pathogens 
in laboratory reagents, laboratory technical error and use of laboratory techniques 
which have not been validated (82).  In this study, this particular tube of growth 
medium had undergone the same incubation as the others in order to ensure that 
there was no contamination prior to inoculation and no deviation from the prescribed 
aseptic technique in sample withdrawal or transfer was noted.  However, it is 
possible that the there was contamination from external sources during the collection 
or transfer of the sample (for example, if somebody sneezed close to the investigator).  
Whilst the laboratory staff did not report any breach in laboratory processes, it is 
possible that the broth was accidently opened in the laboratory which could have 
allowed spurious contamination at that stage. 
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5.3.2 Possible explanations of why more samples were not found to be 
contaminated  
 
The one sample which was found to be contaminated was from a multi-dose syringe 
taken at the beginning of the study period.  No other contamination in either multi-
dose or control syringes was noted.  Possible explanations for this are considered 
below. 
 
5.3.2.1 Lack of contamination as an explanation 
Since syringes were prepared with clean hands in the theatre environment and all 
aliquots were withdrawn under strict aseptic conditions, it is possible that there 
simply was no contamination of the remaining syringes.  As discussed in 2.6, the 
literature suggests that contamination of multi-dose drug containers is exceedingly 
rare in general.  
 
5.3.2.2 Possibly microbes were unable to survive in the drug mixture 
It is conceivable that some microbes may have been inoculated into the syringes 
under investigation, but were unable to survive or multiply in the drug mixture.  As 
illustrated in Chapter 2, there is conflicting evidence in previous literature as to 
whether this drug mixture can be expected to support the growth of microbes.  The 
final concentration of bupivacaine in the drug mixture investigated was 4mg.ml-1, 
which is greater than the minimum inhibitory concentration (MIC) found by many 
previous authors for several species (14,34,39,48-54).  It is possible that the 
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antimicrobial activity of bupivacaine dominated over the potential for the dextrose in 
the mixture to provide nutritional support to any microbes which may have 
contaminated the syringe.  The concern with this explanation, however, is that there 
are some pathogens which seem to be resistant to the antimicrobial effects of 
bupivacaine, such Pseudomonas aeruginosa (33,39,52,53), which may be allowed to 
multiply in the drug mixture should contamination take place.  
 
5.3.2.3 The possibility that contaminants were not cultured 
Since the final concentration of bupivacaine in the thioglycollate broth was 0.06%, it 
is unlikely that the bupivacaine would continue to inhibit microbial growth after 
inoculation into the broth since this is far below the MIC described by previous 
authors for various species (14,33,34,39,48-54).  Thioglycollate broth was selected 
because it is an all-purpose growth medium which is useful in isolating a wide range 
of organisms and is good a yielding recovery from low numbers of microbes in the 
initial inoculum.  However, there are some species which are fastidious and may not 
grow under the laboratory conditions presented.  The broth was incubated in an 
aerobic incubator only, and this could conceivably have decreased the growth of any 
anaerobes present.  However, it was assumed that the broth at the bottom of the tube 
would contain sufficiently low oxygen tensions to allow for the growth of anaerobic 
micro-organisms.  
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5.4 Discussion of secondary outcomes 
 
This pilot study was not sufficiently powered to provide robust evidence to comment 
the secondary outcomes.  Far greater sample numbers would be needed to show 
statistically significant correlations. However, the following were noted. 
 
5.4.1 Discussion regarding theatre temperature 
 
It was interesting to note that the sample which yielded microbial growth was taken 
with a theatre temperature of 22,6 °C, with the lowest recorded temperature during 
the study period being 22,4°C (Table 4.4).  This could be coincidence (and would 
certainly be if this is a spurious result), or could be related to the decreased 
antimicrobial properties of bupivacaine at lower temperatures (2.3.5). 
 
5.4.2 Discussion regarding numbers of cases 
 
There was very little difference in the numbers of theatre cases having been 
commenced at corresponding sampling intervals, with the maximum range in any 
sampling interval being 3 cases (4.4.2).  It is therefore not possible to comment upon 
any relationship between theatre traffic (for which number of cases was being used 
as a marker) and the risk of microbial contamination of the contents of the syringes. 
Between four and seven cases were done in the theatre over a twelve hour period.  
Therefore, with two obstetric theatres working, the estimate used in the design of this 
study of one caesarean section per hour was fairly accurate.  
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5.5 Legal implications of the protocol 
 
The drug mixture under consideration contains fentanyl, which is a schedule six drug. 
As stated in the General Regulations in terms of the Medicines and Related 
Substances Act, 1965 (Act No 101 of 1965), published by the Department of Health in 
2003, all schedule six substances need to logged in a register where they are 
dispensed (79).  According to Regulation 11 of this Notice, the following information 
needs to be kept: 
 (a) the name of the medicine or scheduled substance; 
 (b) the date on which the prescription was dispensed; 
 (c) the dosage form and quantity of the medicine or scheduled substance; 
 (d) the name and address of the patient, or, in the case of a prescription  
  issued by a veterinarian, the name and address of the person to whom 
  the medicine or scheduled substance was sold; 
  (e) where applicable, the name of the medical practitioner, dentist,  
  veterinarian or any other authorised person who issued the   
  prescription;  and 
 (f) prescription reference number (79). 
 
However, the Regulations do not state that each ampoule must be registered to a 
single patient.  Therefore, it would fulfil legal requirements if each patient who 
received a portion of the mixture were registered as having received the equivalent 
amount of fentanyl.  The concentration of fentanyl in the mixture is 10μg.ml-1.  If ten 
patients each receive 2ml of the mixture, the register should document that they each 
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received 20μg of fentanyl.  In this way, all fentanyl dispensed will be accounted for 
and the names of all patients who received fentanyl will appear in the register. 
 
5.6 Suggestions for future studies 
 
The purpose of this pilot study was to establish whether there is a clear and 
undeniable risk to patients in using this protocol, in which case further investigation 
would be unwarranted and the protocol should be immediately abandoned.  
However, this clear risk was not established with the simple methodology used in this 
pilot study.  To avoid ambiguity in results, the methodology of future work will 
necessarily be more complicated and sample numbers will be greater.  In view of the 
outcomes of this pilot, the following recommendations are made for future work. 
 
5.6.1 Recommendations to make results more universally applicable 
 
5.6.1.1 Involvement of multiple investigators 
Since it would appear that aseptic technique is important (17), but not standardised 
(27), it would seem prudent to include samples from drug mixtures prepared by 
many different anaesthetists.  Alternatively, one investigator could repeat the 
procedure using different interpretations of the aseptic technique. 
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5.6.1.2 Investigations carried out in different theatres 
Likewise, samples taken from syringes prepared in many different theatres which 
service different patient populations would provide evidence which would be 
applicable to more clinical situations.  
 
5.6.1.3 Use of drugs produced by various manufacturers 
The drugs used in the study should be obtained from as many different suppliers as 
possible, since differences in manufacturing processes may alter results. 
 
5.6.1.4 Use of more diverse microbiological investigations 
To ensure that all possible organisms causing contamination are cultured, a greater 
variety of growth media should be used, and these should be incubated in both 
aerobic and anaerobic incubators. 
 
5.6.2 Recommendations to decrease the chance of ambiguous results 
 
5.6.2.1 Increased sample size 
Part of decreasing the ambiguity of the results obtained in this pilot study will include 
using greater sample numbers. As explained in 5.2.3.2, the results obtained in this 
study suggest that 581 syringe pairs would be needed in order to assess a 5% 
difference in contamination rates between control- and multi-dose syringes. 
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5.6.2.2 Transfer of samples in a sterile environment 
It is of great benefit to prepare the drug mixtures and withdraw samples from the 
syringes in the theatre environment as this exposes the contents to conditions akin to 
those in the clinical context.  However, transferring the samples into culture media in 
the theatre environment offers additional opportunity for spurious contamination of 
the culture medium.  Therefore, the samples withdrawn from the syringes should be 
sealed in an air-tight container and then transported to the laboratory.  Here, the 
samples can be inoculated into growth medium under a laminar flow hood, which 
would decrease the risk of extrinsic contamination. 
 
5.6.2.3 Processing of samples at multiple different laboratories 
Ideally, multiple samples should be withdrawn at each time period and sent to 
different laboratories.  This would give a comparison in the event of a positive culture 
result.  If all laboratories give the same result, it can be assumed that this is a true 
positive result.  Should only one of the laboratories give a positive result, it would be 
more likely that this is a spurious result.  Practicality and funding would dictate how 
many laboratories could be utilised. 
 
5.7 Summary of discussion 
 
In this chapter, the conclusions drawn from the results of this pilot study have been 
explored.  This pilot study does not show conclusively that the protocol being 
examined poses risk to patients.  In order to gain a more conclusive result, 
methodology of a future study would have to be more complicated than this pilot to 
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avoid ambiguous results, and the sample size will need to be greater.  Further, in the 
clinical setting, care would need to be taken in keeping a register of the fentanyl used 
in order to comply with legislation.  
 
This pilot study has achieved the intention of testing methodology and providing 
some guidelines for sample sizes needed for future studies.  However, in order to gain 
a clear understanding of the topic, a great deal of further research is required. 
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CHAPTER 6: CONCLUSIONS 
 
6.1 Implications of this study of resource utilisation 
 
The enormous case load which is placed upon public hospitals in developing 
countries mandates that any measures which save costs without decreasing the 
quality of health care should be considered.  At CHBH, there is an average of over 600 
caesarean sections performed per month (77).  With such a great number of 
caesarean sections, the protocol for mixing and using drugs reviewed in this study 
could potentially save the South African Department of Health over R54 000,00 per 
annum (Appendix F).  Purely from a financial view, if there is a real risk to patient 
safety in using this protocol, then the cost-saving implications in terms of the drugs 
used would be negated by the far greater financial burden of treating a patient with 
an infectious complication of spinal anaesthesia.  Naturally, there are also ethical and 
philanthropic considerations to be taken aside from the purely financial factors.  
However, if it can be shown that the risk is no greater using this protocol than in 
opening new ampoules for each patient, consideration should be given to instituting 
this protocol as a means of sound resource utilisation. 
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6.2 Future work to be done 
 
This initial study failed to show conclusively that the use of this protocol increases 
risk to patient well-being.  However, there is a great deal more work which needs to 
be done in order to assess what risk there is.  In order to do this, a far broader study 
will need to be undertaken.  This will include larger sample numbers, as discussed in 
Chapter 4, and altering methodology employed, as discussed in Chapter 5.  
 
Should such studies indicate that the risk to patients is no greater when using the 
multi-dose protocol than when using single-dose ampoules, the protocol may be 
accepted for clinical use in resource-limited environments.  In this case, ongoing audit 
should be carried out to survey for infectious complications as discussed in 2.2.  At 
this stage, it would be useful to compare incidence of complications between centres 
which use single-dose ampoules for individual patients only (6,7), those which use 
single-dose ampoules for multiple patients (8) and those which use the multi-dose 
protocol under investigation in this study. 
 
6.3 Closing remarks 
 
Currently accepted guidelines on the use of multi-dose syringes in the anaesthetic 
environment are based largely upon the assumption of good practice rather than 
evidence (6,7,29).  However, the reality in resource-limited settings is that drugs used 
for spinal anaesthesia are often in short supply and, as a result, practitioners 
regularly use single-dose ampoules for more than one patient (8).  Therefore, it is of 
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utmost importance to establish appropriate, evidence-based guidelines to optimise 
resource utilisation without compromising patient safety.  
 
This pilot study is the first step taken towards establishing this evidence in 
connection with the protocol for preparing a drug mixture for spinal anaesthetic in a 
multi-dose syringe.   It is hoped that future work based upon this pilot study will 
assist in establishing such appropriate guidelines, which take cognisance of the 
reality of constraints in resource-poor environments whilst striving to ensure patient 
safety and well-being.
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APPENDICES 
 
APPENDIX A: Protocol for drug preparation for spinal anaesthesia at Chris Hani 
Baragwanath Hospital 
 
OPTIONS FOR INTRATHECAL INJECTIONS FOR CAESAREAN SECTION 
 
 
OPTION 1 
 
2.5ml heavy bupivacaine (0.5%) 
 
Use premixed, or mix 2.25ml bupivacaine with 0.25ml 50% dextrose. 
 
 
OPTION 2 
 
2.0ml volume, with heavy bupivacaine and fentanyl 12-20μg 
 
Using a 20ml syringe, draw up 16ml of heavy bupivacaine. Add 1-2amps (100-200μg) 
fentanyl. 
 
If you added 1 amp (total 18ml), then a 2.0ml spinal will contain 8.88mg of 
bupivacaine, and 11.11μg of fentanyl. 
 
If you added 2 amps (total 20ml), then a 2.0ml spinal will contain 8mg of bupivacaine, 
and 20μg of fentanyl. 
 
SOME INFORMATION 
 
Adding fentanyl to intrathecal bupivacaine improves both the quality and duration 
of the block. It allows for lower doses of bupivacaine to be used, thus decreasing the 
haemodynamic effects of the sympathetic block achieved by bupivacaine alone. 
 
Concerns regarding the use of fentanyl relate to its side effects. There may be 
pruritus (usually limited to the nose, for some reason, and for a short period only), 
nausea/vomiting (which is minimal with doses below 50μg, and a lot less of a 
problem than the nausea associated with hypotension), and there is always a concern 
about respiratory depression. Intrathecal doses of up to 20μg have repeatedly been 
found to be safe, and patients are not required to be monitored postoperatively for 
longer than the usual recovery period. 
 
 
Dr P Penfold 
Senior Consultant #6722 
Obstetric Anaesthesia 
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APPENDIX B: Ethics Waiver
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APPENDIX C: Faculty of Health Sciences Post-Graduate Committee Approval 
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APPENDIX D: Permission from Medical Superintendent to conduct research at 
Chris Hani Baragwanath Hospital 
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APPENDIX E: Data sheet 
 
INVESTIGATION INTO MICROBIAL GROWTH IN MULTI-DOSE SYRINGE 
DATA SHEET 
        
SYRINGE PAIR STUDY NUMBER:     
Date:      
        
Sample 
number 
 
 
Lab Request Bar 
Code 
Lab number Time 
sample 
taken 
 
Temp (°C) 
 when 
sample 
taken 
Time 
sample at 
lab 
 
Microbial 
growth  
 
Species Identification 
 
CS – 00 
  
  
 
      
MS – 00 
  
  
 
      
MS – 04 
  
  
 
      
MS – 08 
  
  
 
      
MS – 12 
  
  
 
      
CS – 12 
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APPENDIX F: Calculation on costs saved using the multi-dose syringe 
 
At current costs, each ampoule of Micro bupivacaine 0.5% with dextrose 4ml costs 
R10,50 on government tender, whilst each ampoule of Fresenius Fentanyl 100 
μg/2ml costs R1,40 on government tender.   According to the protocol in Appendix 1, 
each 20ml syringe contains four ampoules of the bupivacaine and two ampoules of 
the fentanyl, which comes to a total cost of R44,80. Assuming a total volume of 2ml of 
drug mixture used for each intrathecal injection, a syringe containing 20ml of drug 
mixture as described in Appendix 1 may be used for 10 patients.  Therefore, using the 
multi-does syringe protocol, the cost per patient is R4,48. 
 
If new ampoules of bupivacaine and a new ampoule of fentanyl are opened for each 
patient, the cost per patient is R11.90 
 
The average number of caesarean sections performed at Chris Hani Baragwanath 
Hospital over the 18 month period starting January 2008 was 608 caesarean sections 
per month.  According to this calculation, the use of the multi-dose syringe protocol 
would save R54 136,32 per annum. 
 
 
 
